

## CURRICULUM VITAE

**Date of Revision:** 04/20/2024

**Name:** Farzad Hadaegh

**Education:** *(Start with the first academic degree according to date; from past to present)*

1. 1985-1992 - MD - Shahid Beheshti University (M.C.)
2. 1992-1995 - Board Certified of Internal Medicine - Shahid Beheshti University (M.C.)
3. 1998-2000 - Board Certified of Endocrinology and metabolism - Shahid Beheshti University (M.C.)

**Career/Academic Appointments:** *(Academic positions should be listed by date from past to present )*

1. 2012 to Now- Professor of Endocrinology and Metabolism, Shahid Beheshti University of Medical

**Administrative Positions:** *(Administrative position should be listed by date from past to present )*

1. 2006 to Now - Head of Prevention of Metabolic Disorders Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences.

**Professional Honors & Recognition:** *(Scientific Awards, incentives and obtained scientific points should be mentioned by date from past to present)*

1. 2008-Distinguished Associate Professor in 9th- Festival of Shahid Beheshti University of Medical Sciences
2. 2010- 4th Rank in 16th , Expert Committee of Clinical and Internal Sciences, Razi Research Festival on Medical Sciences
3. 2011- 2nd Rank in 17th, Expert Committee of Clinical and Internal Sciences, Razi Research Festival on Medical Sciences
4. 2011- Distinguished Associate Professor in 12th - Festival of Shahid Beheshti University of Medical Sciences
5. 2012- National Distinguished Researcher, 13th Acknowledgement of Distinguished Researchers and Technologists Festival
6. 2014- Outstanding Researcher in Endocrinology and Metabolism (Avicenna Prize) in 10th International Congress of Endocrine Disorders
7. 2015- Distinguished Professor (Clinical Medicine) in 16th , Festival of Shahid Beheshti University of Medical Sciences.
8. 2017- Faculty member with h Index of 20 or higher ( $\geq 20$ ) & Total Citation  $\geq 1000$  in 18th Festival of Shahid Beheshti University of Medical Sciences
9. 2018- Faculty member with h Index of 20 or higher ( $\geq 20$ ) & Total Citation  $\geq 1000$  in 19th Festival

of Shahid Beheshti University of Medical Sciences

10. 2019- Faculty member with h Index of 25 or higher ( $\geq 25$ ) & Total Citation  $\geq 1000$  in 20th Festival of Shahid Beheshti University of Medical Sciences
11. 2019- Top Researcher in Diabetes Research- Iranian Diabetes Academy
12. 2020- 3rd Rank in Health and clinical sciences committee, 26th Razi Research Festival on Medical Sciences
13. 2020- Faculty member with h Index of 25 or higher ( $\geq 25$ ) & Total Citation  $\geq 1000$  in 21th Festival of Shahid Beheshti University of Medical Sciences
14. 2021- Distinguished Professor (Clinical Medicine) in 22th, Festival of Shahid Beheshti University of Medical Sciences.
15. 2021-Faculty member with h Index of 28 or higher ( $\geq 28$ ) & Total Citation  $\geq 1000$  in 22th Festival of Shahid Beheshti University of Medical Sciences
16. 2023- The eminent scholarly rank within the top 1% of the Essential Science Indicators (ESI) and the top 2% according to the Stanford Elsevier database.

**Grant History:** *(If you have national or international grants, mention them by date from past to present)*

1. 2017 to Now (3 proposal) - National Institute for Medical Research Development (NIMAD)

**Completed Grants:** *(If you have any national or international completed grants, mention them by date from past to present)*

1. 2017 to Now (5 proposal) - National Institute for Medical Research Development (NIMAD)

**Lectures, Courses, Web-based Education:** *(If you have presented or participated in any lecture, educational courses or web-based education, during the last 5 years mention their subject or title)*

1. 2021 - Cardiovascular Safety and Efficacy of Metformin as the First Line Medication in the Management of Type 2 Diabetes
2. 2021 - Approach of Dyslipidemia for Population with Diabetes
3. 2021 - High cardiovascular risk definition, Real status of GLP1 analogs and Na-Glu 2 inhibitors in the management of patients with type 2 diabetes
4. 2021 - Prevention of CVD outcomes among patients with T2DM with or at high CVD risk: to start or not start with metformin
5. 2021 - Primary prevention in pre-diabetes: The role of Pharmacotherapy
6. 2021 - The Role of SGLT2-I in Primary Prevention of Cardio-renal Outcomes for Patients with Diabetes
7. 2021 - The Status of SGLT2-I in Primary Prevention of Cardio-renal Complication Among Patient With Diabetes
8. 2021 - The Status of SGLT2-I in Primary Prevention of Cardio-renal Complication Among Patient With Diabetes
9. 2022 - Approach of Dyslipidemia for Population with Diabetes
10. 2022 - Approach to Blood Pressure Control for Population with Diabetes
11. 2022 - Case presentation panel: The importance of communication between clinicians and laboratories
12. 2022 - COVID-19 and Thyroid
13. 2022 - Diabetic Dyslipidemia Impact & Complication

14. 2023 - Approach to Cardiovascular Risk Factor Control Among Patients with Diabetes (Hypertension and Diabetic Kidney Disease)
15. 2023 - Approach to the Management of Patients with Diabetes
16. 2023 - Cardiovascular Kidney Metabolic Health
17. 2023 - Management of Dyslipidemia among Patients with Diabetes
18. 2023 - Obesity: New Insights into Treatment
19. 2023 - Panel Discussion: Updates in Mitigating ASCVD Risk
20. 2023 - Presentation of the Patient with Weakness of Four Extremities
21. 2023 - Prevention of CVD Outcomes among Patients with T2DM at High CVD Risk: to Start or not Start with Metformin
22. 2023 - Prevention of CVD outcomes among patients with T2DM with or at high CVD risk: to start or not start with metformin
23. 2023 - Status of Combination Therapy (Single-pill Combination) in the Management of Hypertension
24. 2023 - Treat to Target vs High Intensity Statin in Patients with CVD
25. 2024 - Real Status of Metformin in the Management of Patients with T2D; from Low Risk to High Risk States

### ➤ **PROFESSIONAL SERVICE:**

**Journal Service:** (*Membership in the editorial board, being a journal director, chief editor or the journal reviewing board or any related position*)

1. 2013 to Now: Assistant editor of International Journal of Endocrinology and Metabolism. (<https://brieflands.com/journals/international-journal-of-endocrinology-and-metabolism>)

**Committees Memberships:** (*Membership in university committees such as ethics committee in research and other professional committees*)

1. 2004 to Now: Membership in Iran Endocrine Society
2. 2004 to Now: Membership in the Research Council of the Research Institute for Endocrine and Metabolism
3. 2004 to Now: Membership in Iran obesity prevention and treatment association
4. 2006 to Now: Membership in Tehran Lipid and Glucose Study Steering Committee
5. 2007 to Now: Membership in the Continuing Education Committee
6. 2016 to Now: Membership in the Clinical Trial Committee
7. 2023 to Now: Membership in the Non-communicable Diseases Committee of the National Institute of Medical Sciences Research Development (NIMAD)

### ➤ **Bibliography:**

**Peer-Reviewed Original Research:** (*List of published articles according to Vancouver style, from past to present*)

1. Hadaegh F\*, Tohidi M, Harati H, Kheirandish M, Rahimi S. Prevalence of gestational diabetes mellitus in southern Iran (Bandar Abbas City). *Endocr Pract.* 2005 Sep-Oct; 11(5):313-8.

2. Hadaegh F, Zabetian A, Harati H, Azizi F. Waist/height ratio as a better predictor of type 2 diabetes compared to body mass index in Tehranian adult men--a 3.6-year prospective study. *Exp Clin Endocrinol Diabetes*. 2006 Jun; 114(6):310-5.
3. Hadaegh F, Harati H, Ghanbarian A, Azizi F. Association of total cholesterol versus other serum lipid parameters with the short-term prediction of cardiovascular outcomes: Tehran Lipid and Glucose Study. *Eur J Cardiovasc Prev Rehabil*. 2006 Aug; 13(4):571-7.
4. Hadaegh F, Zabetian A, Harati H, Azizi F. The prospective association of general and central obesity variables with incident type 2 diabetes in adults, Tehran lipid and glucose study. *Diabetes Res Clin Pract*. 2007 Jun; 76(3):449-54.
5. Zabetian A, Hadaegh F\*, Azizi F. Prevalence of metabolic syndrome in Iranian adult population, concordance between the IDF with the ATPIII and the WHO definitions. *Diabetes Res Clin Pract*. 2007 Aug; 77(2):251-7.
6. Hadaegh F, Harati H, Zabetian A, Azizi F. Seasonal variability of serum lipids in adults: Tehran Lipid and Glucose Study. *Med J Malaysia*. 2006 Aug; 61(3):332-8.
7. Hadaegh F\*, Zabetian A, Harati H, Azizi F. Metabolic syndrome in normal-weight Iranian adults. *Ann Saudi Med*. 2007 Jan-Feb; 27(1):18-24
8. Hadaegh F\*, Harati H, Ghasemi A, Tohidi M, Zabetian A, Mehrabi Y, Azizi F. Using common clinical data improves the prediction of abnormal glucose tolerance by the new criteria of impaired fasting glucose: Tehran lipid and glucose study. *Diabetes Res Clin Pract*. 2007 Sep; 77(3):459-64.
9. Hadaegh F, Esmailzadeh A, Azizi F. Metabolic risks in individuals with normal body mass index and normal waist circumference. *Eur J Cardiovasc Prev Rehabil*. 2007 Apr; 14(2):200-7.
10. Tohidi M, Hadaegh F\*, Harati H, Azizi F. C-reactive protein in risk prediction of cardiovascular outcomes: Tehran Lipid and Glucose Study. *Int J Cardiol*. 2009 Mar 6; 132(3):369-74.
11. Hadaegh F\*, Ghasemi A, Padyab M, Tohidi M, Azizi F. The metabolic syndrome and incident diabetes: Assessment of alternative definitions of the metabolic syndrome in an Iranian urban population. *Diabetes Res Clin Pract*. 2008 May; 80(2):328-34.
12. Hadaegh F\*, Bozorgmanesh MR, Ghasemi A, Harati H, Saadat N, Azizi F. High prevalence of undiagnosed diabetes and abnormal glucose tolerance in the Iranian urban population: Tehran Lipid and Glucose Study. *BMC Public Health*. 2008 May 24; 8: 176.
13. Zabetian A, Hadaegh F\*, Azizi F. Relationship between metabolic syndrome and its components with coronary heart disease in Iranian men and women. *Exp Clin Endocrinol Diabetes*. 2008 Oct; 116(9):525-31.
14. Tohidi M, Harati H, Hadaegh F\*, Mehrabi Y, Azizi F. Association of liver enzymes with incident type 2 diabetes: A nested case control study in an Iranian population. *BMC Endocr Disord*. 2008 Jun 5; 8:5.
15. Bozorgmanesh MR, Hadaegh F\*, Padyab M, Mehrabi Y, Azizi F. Temporal changes in anthropometric parameters and lipid profile according to body mass index among an adult Iranian urban population. *Ann Nutr Metab*. 2008; 53(1):13-22.
16. Hadaegh F\*, Khalili D, Ghasemi A, Tohidi M, Sheikholeslami F, Azizi F. Triglyceride/HDL-cholesterol ratio is an independent predictor for coronary heart disease in a population of Iranian men. *Nutr Metab Cardiovasc Dis*. 2009 Jul; 19(6):401-8.
17. Azizi F, Ghanbarian A, Momenan AA, Hadaegh F, Mirmiran P, Hedayati M, Mehrabi Y, Zahedi-Asl S; Tehran Lipid and Glucose Study Group. Prevention of non-communicable disease in a population in nutrition transition: Tehran Lipid and Glucose Study phase II. *Trials*. 2009 Jan 25; 10:5.
18. Hadaegh F\*, Zabetian A, Tohidi M, Ghasemi A, Sheikholeslami F, Azizi F. Prevalence of metabolic syndrome by the Adult Treatment Panel III, International Diabetes Federation, and World Health Organization definitions and their association with coronary heart disease in an elderly Iranian population. *Ann Acad Med Singapore*. 2009 Feb; 38(2):142-9.
19. Harati H, Hadaegh F\*, Tohidi M, Azizi F. Impaired fasting glucose cutoff value of 5.6 mmol/l combined with other cardiovascular risk markers is a better predictor for incident Type 2 diabetes than the 6.1 mmol/l value: Tehran lipid and glucose study. *Diabetes Res Clin Pract*. 2009 Jul; 85(1):90-5.

20. Azizi F, Farahani ZK, Ghanbarian A, Sheikholeslami F, Mirmiran P, Momenan AA, Asl SZ, Hadaegh F, Eskandari F. Familial aggregation of the metabolic syndrome: Tehran Lipid and Glucose Study. *Ann Nutr Metab.* 2009; 54(3):189-96.
21. Zabetian A, Hadaegh F\*, Sarbakhsh P, Azizi F. Weight change and incident metabolic syndrome in Iranian men and women; a 3 year follow-up study. *BMC Public Health.* 2009 May 13; 9: 138.
22. Hadaegh F\*, Shafiee G, Azizi F. Anthropometric predictors of incident type 2 diabetes mellitus in Iranian women. *Ann Saudi Med.* 2009 May-Jun; 29(3):194-200.
23. Hadaegh F, Harati H, Ghanbarian A, Azizi F. Prevalence of coronary heart disease among Tehran adults: Tehran Lipid and Glucose Study. *East Mediterr Health J.* 2009 Jan-Feb; 15(1):157-66
24. Harati H, Hadaegh F\*, Saadat N, Azizi F. Population-based incidence of Type 2 diabetes and its associated risk factors: results from a six-year cohort study in Iran. *BMC Public Health.* 2009 Jun 16; 9: 186.
25. Hadaegh F\*, Khalili D, Fahimfar N, Tohidi M, Eskandari F, Azizi F. Glucose intolerance and risk of cardiovascular disease in Iranian men and women: results of the 7.6-year follow-up of the Tehran Lipid and Glucose Study (TLGS). *Endocrinol Invest.* 2009 Oct; 32(9):724-30.
26. Hadaegh F, Zabetian A, Sarbakhsh P, Khalili D, James WP, Azizi F. Appropriate cutoff values of anthropometric variables to predict cardiovascular outcomes: 7.6 years follow-up in an Iranian population. *Int J Obes (Lond).* 2009 Dec; 33(12):1437-45.
27. Hadaegh F\*, Shafiee G, Ghasemi A, Sarbakhsh P, Azizi F. Impact of metabolic syndrome, diabetes and prediabetes on cardiovascular events: Tehran Lipid and Glucose Study. *Diabetes Res Clin Pract.* 2010 Mar; 87(3):342-347.
28. Bozorgmanesh M, Hadaegh F\*, Zabetian A, Azizi F. San Antonio heart study diabetes prediction model applicable to a Middle Eastern population? Tehran glucose and lipid study. *Int J Public Health.* 2010 Aug; 55(4):315-23.
29. Tohidi M, Hatami M, Hadaegh F\*, Safarkhani M, Harati H, Azizi F. Lipid measures for prediction of incident cardiovascular disease in diabetic and non-diabetic adults: results of the 8.6 years follow-up of a population based cohort study. *Lipids Health Dis.* 2010 Jan 23; 9:6.
30. Rostambeigi N, Shaw JE, Atkins RC, Ghanbarian A, Cameron AJ, Forbes A, Momenan A, Hadaegh F, Mirmiran P, Zimmet PZ, Azizi F, Tonkin AM. Waist circumference has heterogeneous impact on development of diabetes in different populations: longitudinal comparative study between Australia and Iran. *Diabetes Res Clin Pract.* 2010 Apr; 88(1):117-24.
31. Azizi F, Khalili D, Aghajani H, Esteghamati A, Hosseinpanah F, Delavari A, Larijani B, Mirmiran P, Mehrabi Y, Kelishadi R, Hadaegh F\*. Appropriate waist circumference cut-off points among Iranian adults: the first report of the Iranian National Committee of Obesity. *Arch Iran Med.* 2010; 13(3):243-4.
32. Bozorgmanesh M, Hadaegh F, Azizi F. Diabetes prediction, Lipid accumulation product, and adiposity measures; 6-year follow-up: Tehran Lipid and Glucose Study. *Lipids Health Dis.* 2010 May 10; 9(1):45.
33. Harati H, Hadaegh F\*, Momenan AA, Ghanei L, Bozorgmanesh MR, Ghanbarian A, Mirmiran P, Azizi F. Reduction in incidence of type 2 diabetes by lifestyle intervention in a middle eastern community. *Am J Prev Med.* 2010 Jun; 38(6):628-636.e1
34. Bozorgmanesh M, Hadaegh F\*, Ghaffari S, Harati H, Azizi F. A simple risk score effectively predicted type 2 diabetes in Iranian adult population: population-based cohort study. *Eur J Public Health.* 2010 Jun 9. [Epub ahead of print]
35. Hadaegh F\*, Hatami M, Tohidi M, Sarbakhsh P, Saadat N, Azizi F. Lipid ratios and appropriate cut off values for prediction of diabetes: a cohort of Iranian men and women. *Lipids Health Dis.* 2010 Aug 17; 9(1):85.
36. Azizi F, Hadaegh F, Khalili D, Esteghamati A, Hosseinpanah F, Delavari A, Larijani B, Mirmiran P, Zabetian A, Mehrabi Y, Kelishadi R, Aghajani H. Appropriate definition of metabolic syndrome among Iranian adults: report of the Iranian National Committee of Obesity. *Arch Iran Med.* 2010 Sep; 13(5):426
37. Bozorgmanesh M, Hadaegh F\*, Azizi F. Predictive performances of Lipid accumulation product vs. adiposity measures for cardiovascular diseases and all-cause mortality; 8.6-year follow-up: Tehran lipid and glucose study. *Lipids Health Dis.* 2010 Sep 16; 9(1):100.

38. Hadaegh F\*, Zabetian A, Khalili D, Safarkhani M, James WP, Azizi F. A new approach to compare the predictive power of metabolic syndrome defined by a joint interim statement versus its components for incident cardiovascular disease in Middle East Caucasian residents in Tehran. *J Epidemiol Community Health*. 2010 Nov 4. [Epub ahead of print]
39. Bozorgmanesh M, Hadaegh F, Azizi F. Transportability of the updated diabetes prediction model from Atherosclerosis Risk in Communities Study to a Middle Eastern adult population: community-based cohort study. *Acta Diabetol*. 2010 Dec 1. [Epub ahead of print]
40. Hadaegh F\*, Fahimfar N, Khalili D, Sheikholeslami F, Azizi F. New and known type 2 diabetes as coronary heart disease equivalent: results from 7.6 year follow up in a Middle East population. *Cardiovasc Diabetol*. 2010 Dec 4;9(1):84. [Epub ahead of print]
41. Hajsheikholeslami F, Hatami M, Hadaegh F, Ghanbarian A, Azizi F. Association of educational status with cardiovascular disease: Tehran Lipid and Glucose Study. *Int J Public Health*. 2010 Dec 9.
42. Tohidi M, Ghasemi A, Hadaegh F, Arbabi S, Hosseini Isfahani F. Intra-erythrocyte Magnesium Is Associated with Gamma-Glutamyl Transferase in Obese Children and Adolescents. *Biol Trace Elem Res*. 2011 Jan 11.
43. Hatami M, Hadaegh F\*, Khalili D, Sheikholeslami F, Azizi F. Family history of diabetes modifies the effect of blood pressure for incident diabetes in Middle Eastern women: Tehran Lipid and Glucose Study. *J Hum Hypertens*. 2011 Feb 3.
44. Bozorgmanesh M, Hadaegh F\*, Azizi F. Predictive accuracy of the 'Framingham's general CVD algorithm' in a Middle Eastern population: Tehran Lipid and Glucose Study. *Int J Clin Pract*. 2011 Mar;65(3):264-73
45. Bozorgmanesh M, Hadaegh F, Sheikholeslami F, Azizi F. Cardiovascular risk and all cause mortality attributable to diabetes: Tehran Lipid and Glucose Study. *J Endocrinol Invest*. 2011 May 17.
46. Hadaegh F\*, Bozorgmanesh M, Safarkhani M, Khalili D, Azizi F. Predictability of body mass index for diabetes: Affected by the presence of metabolic syndrome?" *BMC Public Health*. 2011 May 25;11(1):383.
47. Bozorgmanesh M, Hadaegh F, Saadat N, Azizi F. Fasting glucose cutoff point: where does the risk terminate? Tehran lipid and glucose study. *Acta Diabetol*. 2011 May 27.
48. Bozorgmanesh M, Hadaegh F, Azizi F. Predictive performance of the visceral adiposity index for a visceral adiposity-related risk: Type 2 Diabetes. *Lipids Health Dis*. 2011 May 27;10(1):88.
49. Bozorgmanesh M, Hadaegh F\*, Zabetian A, Azizi F. Impact of hip circumference and height on incident diabetes: results from 6-year follow-up in the Tehran Lipid and Glucose Study. *Diabet Med*. 2011 May 31.
50. Hadaegh F\*, Shafiee G, Hatami M, Azizi F. Systolic and diastolic blood pressure, mean arterial pressure and pulse pressure for prediction of cardiovascular events and mortality in a Middle Eastern population. *Blood Press*. 2011 Jun 16.
51. Bozorgmanesh M, Hadaegh F\*, Mehrabi Y, Azizi F. A point-score system superior to blood pressure measures alone for predicting incident hypertension: Tehran Lipid and Glucose Study. *J Hypertens*. 2011 Aug;29(8):1486-93
52. Tohidi M, Hatami M, Hadaegh F, Azizi F. Triglycerides and triglycerides to high-density lipoprotein cholesterol ratio are strong predictors of incident hypertension in Middle Eastern women. 2011 Jul 21.
53. Samadi S, Bozorgmanesh M, Khalili D, Momenan A, Sheikholeslami F, Azizi F, Hadaegh F\*. Hypertriglyceridemic waist: The point of divergence for prediction of CVD vs. mortality: Tehran Lipid and Glucose Study. *Int J Cardiol*. 2011 Sep 15.
54. Hadaegh F, Hatami M, Mohebi R, Hasheminia M, Bozorgmanesh M, Sheikholeslami F, Azizi F. Electrocardiography-defined silent CHD and risk of cardiovascular events among diabetic patients in a Middle Eastern population. *Eur J Cardiovasc Prev Rehabil*. 2011 Oct 19.
55. Hadaegh F, Zabetian A, Khalili D, Safarkhani M, Philip T James W, Azizi F. A new approach to compare the predictive power of metabolic syndrome defined by a joint interim statement versus its components for incident cardiovascular disease in Middle East Caucasian residents in Tehran. *J Epidemiol Community Health*. 2012 May;66(5):427-32.

56. Bozorgmanesh M, Hadaegh F\*, Azizi F. A simple clinical model predicted diabetes progression among prediabetic individuals. *Diabetes Res Clin Pract.* 2012 Aug;97(2):e34-6
57. Hatami M, Tohidi M, Mohebi R, Khalili D, Azizi F, Hadaegh F. Adolescent lipoprotein classifications according to National Health and Nutrition Examination Survey (NHANES) vs. National Cholesterol Education Program (NCEP) for predicting abnormal lipid levels in adulthood in a Middle East population. *Lipids Health Dis.* 2012 Aug 31;11:107.
58. Bozorgmanesh M, Hadaegh F\*, Sheikholeslami F, Azizi F. Cardiovascular risk and all-cause mortality attributable to diabetes: Tehran lipid and glucose study. *J Endocrinol Invest.* 2012 Jan;35(1):14-20
59. Hadaegh F\*, Jahangiri Noudeh Y, Tohidi M, Vatankhah N, Khalili D, Mohebi R, Azizi F. Change in general and central adiposity measures in prediction of incident dysglycemia; Tehran Lipid and Glucose Study. *Prev Med.* 2012 Dec;55(6):608-12.
60. Khalili D, Hadaegh F\*, Soori H, Steyerberg EW, Bozorgmanesh M, Azizi F. Clinical usefulness of the Framingham cardiovascular risk profile beyond its statistical performance: the Tehran Lipid and Glucose Study. *Am J Epidemiol.* 2012 Aug 1;176(3):177-86.
61. Hadaegh F\*, Mohebi R, Cheraghi L, Tohidi M, Moghaddam NB, Bozorgmanesh M, Sheikholeslami F, Azizi F. Do different metabolic syndrome definitions predict cerebrovascular events and coronary heart disease independent of their components?: 9 years follow-up of the tehran lipid and glucose study. *Stroke.* 2012 Jun;43(6):1669-71.
62. Khalili D, Hadaegh F\*, Fahimfar N, Shafiee G, Sheikholeslami F, Ghanbarian A, Azizi F. Does an electrocardiogram add predictive value to the rose angina questionnaire for future coronary heart disease? 10-year follow-up in a Middle East population. *J Epidemiol Community Health.* 2012 Dec;66(12):1104-9.
63. Hadaegh F\*, Mohebi R, Bozorgmanesh M, Saadat N, Sheikholeslami F, Azizi F. Electrocardiographic abnormalities improve classification of coronary heart disease risk in women: Tehran Lipid and Glucose Study. *Atherosclerosis.* 2012 May;222(1):110-5.
64. Hadaegh F\*, Hatami M, Mohebi R, Hasheminia M, Bozorgmanesh M, Sheikholeslami F, Azizi F. Electrocardiography-defined silent CHD and risk of cardiovascular events among diabetic patients in a Middle Eastern population. *Eur J Prev Cardiol.* 2012 Dec;19(6):1227-33
65. Khalili D, Mosavi-Jarrahi A, Eskandari F, Mousavi-Jarrahi Y, Hadaegh F, Mohagheghi M, Azizi F. Evaluation of cause of deaths' validity using outcome measures from a prospective, population based cohort study in Tehran, Iran. *PLoS One.* 2012;7(2):e31427.
66. Hatami M, Hadaegh F, Khalili D, Sheikholeslami F, Azizi F. Family history of diabetes modifies the effect of blood pressure for incident diabetes in Middle Eastern women: Tehran Lipid and Glucose Study. *J Hum Hypertens.* 2012 Feb;26(2):84-90
67. Bozorgmanesh M, Hadaegh F\*, Saadat N, Azizi F. Fasting glucose cutoff point: where does the risk terminate? Tehran lipid and glucose study. *Acta Diabetol.* 2012 Oct;49(5):341-8
68. Tohidi M, Hasheminia M, Mohebi R, Khalili D, Hosseinpanah F, Yazdani B, Nasiri AA, Azizi F, Hadaegh F\*. Incidence of chronic kidney disease and its risk factors, results of over 10 year follow up in an Iranian cohort. *PLoS One.* 2012;7(9):e45304
69. Khalili S, Hatami M, Hadaegh F\*, Sheikholeslami F, Azizi F. Prediction of cardiovascular events with consideration of general and central obesity measures in diabetic adults: results of the 8.4-year follow-up. *Metab Syndr Relat Disord.* 2012 Jun;10(3):218-24
70. Shafiei B, Hoseinzadeh S, Fotouhi F, Malek H, Azizi F, Jahed A, Hadaegh F, Salehian M, Parsa H, Javadi H, Assadi M. Preoperative <sup>99m</sup>Tc-sestamibi scintigraphy in patients with primary hyperparathyroidism and concomitant nodular goiter: comparison of SPECT-CT, SPECT, and planar imaging. *Nucl Med Commun.* 2012 Oct;33(10):1070-6
71. Mohammadreza B, Farzad H\*, Davoud K, Fereidoun Prof AF. Prognostic significance of the complex "Visceral Adiposity Index" vs. simple anthropometric measures: Tehran lipid and glucose study. *Cardiovasc Diabetol.* 2012 Mar 7;11:20.
72. Fahimfar N, Khalili D, Mohebi R, Azizi F, Hadaegh F\*. Risk factors for ischemic stroke; results from 9 years of follow-up in a population based cohort of Iran. *BMC Neurol.* 2012 Oct 2;12:117.

73. Bozorgmanesh M, Hadaegh F\*, Sheikholeslami F, Ghanbarian A, Azizi F. Shadow of diabetes over cardiovascular disease: comparative quantification of population-attributable all-cause and cardiovascular mortality. *Cardiovasc Diabetol*. 2012 Jun 15;11:69
74. Hadaegh F, Shafiee G, Hatami M, Azizi F. Systolic and diastolic blood pressure, mean arterial pressure and pulse pressure for prediction of cardiovascular events and mortality in a Middle Eastern population. *Blood Press*. 2012 Feb;21(1):12-8.
75. Tohidi M, Hatami M, Hadaegh F, Azizi F. Triglycerides and triglycerides to high-density lipoprotein cholesterol ratio are strong predictors of incident hypertension in Middle Eastern women. *J Hum Hypertens*. 2012 Sep;26(9):525-32.
76. Bozorgmanesh M, Hadaegh F\*, Mohebi R, Ghanbarian A, Eskandari F, Azizi F. Diabetic population mortality and cardiovascular risk attributable to hypertension: A decade follow-up from the Tehran Lipid and Glucose Study. *Blood Press*. 2013 Mar 5. [Epub ahead of print
77. Mohebi R, Bozorgmanesh M, Azizi F, Hadaegh F. Effects of Obesity on the Impact of Short-Term Changes in Anthropometric Measurements on Coronary Heart Disease in Women. *Mayo Clin Proc*. 2013
78. Hadaegh F\*, Mohebi R, Khalili D, Hasheminia M, Sheikholeslami F, Azizi F. High normal blood pressure is an independent risk factor for cardiovascular disease among middle-aged but not in elderly populations: 9-year results of a population-based study. *J Hum Hypertens*. 2013 Jan;27(1):18-23
79. Tohidi M, Bozorgmanesh M, Mohebi R, Khalili D, Saadat N, Khorrami N, Azizi F, Hadaegh F\*. Non-linear association between 25-hydroxyvitamin D and the incidence of Type 2 diabetes: a community-based nested case-control study. *Diabet Med*. 2013 Mar 18.
80. Bozorgmanesh M, Ghoreishian H, Mohebi R, Azizi F, Hadaegh F. Sex-specific predictors of the prehypertension-to-hypertension progression: community-based cohort of a West-Asian population. *Eur J Prev Cardiol*. 2013 Mar 11.
81. Jahangiri Noudeh Y, Hadaegh F\*, Vatankhah N, Momenan AA, Saadat N, Khalili D, Azizi F. Wrist circumference as a novel predictor of diabetes and prediabetes: results of cross-sectional and 8.8-year follow-up studies. *J Clin Endocrinol Metab*. 2013 Feb;98(2):777-84. Epub 2013 Jan 22.
82. Mohebi R, Bozorgmanesh M, Sheikholeslami F, Azizi F, Hadaegh F\*. Contribution of glomerular filtration rate to 10-year cardiovascular and mortality risk among hypertensive adults: tehran lipid and glucose study. *J Clin Hypertens (Greenwich)*. 2013 May;15(5):350-8.
83. Bozorgmanesh M, Hadaegh F, Azizi F. Transportability of the updated diabetes prediction model from Atherosclerosis Risk in Communities Study to a Middle Eastern adult population: community-based cohort study. *Acta Diabetol*. 2013 Apr;50(2):175-81.
84. Samadi S, Bozorgmanesh M, Khalili D, Momenan A, Sheikholeslami F, Azizi F, Hadaegh F. Hypertriglyceridemic waist: The point of divergence for prediction of CVD vs. mortality: Tehran Lipid and Glucose Study. *Int J Cardiol*. 2013 May 10;165(2):260-5.
85. Mohebi R, Bozorgmanesh M, Azizi F, Hadaegh F\*. Effects of obesity on the impact of short-term changes in anthropometric measurements on coronary heart disease in women. *Mayo Clin Proc*. 2013 May;88(5):487-94.
86. Tohidi M, Mohebi R, Cheraghi L, Hajsheikholeslami F, Aref S, Nouri S, Azizi F, Hadaegh F\*. Lipid profile components and incident cerebrovascular events versus coronary heart disease; the result of 9 years follow-up in Tehran Lipid and Glucose Study. *Clin Biochem*. 2013 Jun;46(9): 716-721.
87. Yadegari H, Bozorgmanesh M, Hadaegh F\*, Azizi F. Non-linear contribution of glucose measures to cardiovascular diseases and mortality: Reclassifying the Framingham's risk categories: A decade follow-up from the Tehran lipid and glucose study. *Int J Cardiol*. 2013;167:1486-1494.
88. Tohidi M, Bozorgmanesh M, Mohebi R, Khalili D, Saadat N, Khorrami N, Azizi F, Hadaegh F. Non-linear association between 25-hydroxyvitamin D and the incidence of Type 2 diabetes: a community-based nested case-control study. *Diabet Med*. 2013 Aug;30(8):934-8.
89. Hadaegh F, Hasheminia M., Loftallian M., Mohebi R., Azizi F., Tohidi M. Incidence of metabolic syndrome over 9 years follow-up; the importance of sex differences in the role of insulin resistance and other risk factors. *PLoS One*. 2013;8(9):E76304



90. Bozorgmanesh M, Hadaegh F, Mohebi R, Ghanbarian A, Eskandari F, Azizi F. Diabetic population mortality and cardiovascular risk attributable to hypertension: A decade follow-up from the Tehran Lipid and Glucose Study. *Blood Press*. 2013 Oct;22(5):317-24.
91. Secular trends in serum lipid levels of a Middle Eastern adult population; 10 years follow up in Tehran lipid and glucose study. *Lipids Health Dis*. 2014 Jan 23;13(1):20. Kheirandish M, Asgari S, Lotfaliany M, Bozorgmanesh M, Saadat N, Tohidi M, Azizi F, Hadaegh F.
92. The effect of community-based education for lifestyle intervention on the prevalence of metabolic syndrome and its components: tehran lipid and glucose study. Azizi F1, Mirmiran P1, Momenan AA1, Hadaegh F 1, Habibi Moeini A1, Hosseini F1, Zahediasl S1, Ghanbarian A1, Hosseinpanah F1; Members of Tehran Lipid and Glucose Study Group. *Int J Endocrinol Metab*. 2013 Summer;11(3):145-53.
93. Metabolic mediators of the effects of body-mass index, overweight, and obesity on coronary heart disease and stroke: a pooled analysis of 97 prospective cohorts with 1.8 million participants. Global Burden of Metabolic Risk Factors for Chronic Diseases Collaboration (BMI Mediated Effects), Lu Y, Hajifathalian K, Ezzati M, Woodward M, Rimm EB, Danaei G. *Lancet*. 2014 Mar 15;383(9921):970-83
94. Age- and sex-specific reference values for fasting serum insulin levels and insulin resistance/sensitivity indices in healthy Iranian adults: Tehran Lipid and Glucose Study. Tohidi M, Ghasemi A, Hadaegh F, Derakhshan A, Chary A, Azizi F. *Clin Biochem*. 2014 Apr;47(6):432-8.
95. The impact of smoking status on 9.3 years incidence of cardiovascular and all-cause mortality among Iranian men. Ehteshami-Afshar S1, Momenan A, Hajshekholeslami F, Azizi F, Hadaegh F. *Ann Hum Biol*. 2014 May;41(3):249-54.
96. Distribution of ideal cardiovascular health in a community-based cohort of Middle East population. Moghaddam MM, Mohebi R, Hosseini F, Lotfaliany M, Azizi F, Saadat N, Hadaegh F. *Ann Saudi Med*. 2014 Mar-Apr;34(2):134-42.
97. Mozaffary A, Bozorgmanesh M, Sheikholeslami F, Azizi F, Eskandari F, Hadaegh F\*. Added value of different metabolic syndrome definitions for predicting cardiovascular disease and mortality events among elderly population: Tehran Lipid and Glucose Study. *Eur J Clin Nutr*. 2014 Jul;68(7):853-8.
98. Derakhshan A1, Sardarinia M1, Khalili D1, Momenan AA1, Azizi F2, Hadaegh F Sex Specific Incidence Rates of Type 2 Diabetes and Its Risk Factors over 9 Years of Follow-Up: Tehran Lipid and Glucose Study. *PLoS One*. 2014 Jul 16;9(7):e102563.
99. Bozorgmanesh M1, Ghoreishian H, Mohebi R, Azizi F, Hadaegh F. Sex-specific predictors of the prehypertension-to-hypertension progression: community-based cohort of a West-Asian population. *Eur J Prev Cardiol*. 2014;21(8):956-963
100. Mohebi R1, Mohebi A2, Ghanbarian A1, Momenan A1, Azizi F3, Hadaegh F. Is systolic blood pressure below 150 mm Hg an appropriate goal for primary prevention of cardiovascular events among elderly population? *J Am Soc Hypertens*. 2014 Jul;8(7):491-7
101. Mohammadreza Bozorgmanesh, Banafsheh Arshi, Farhad Sheikholeslami, Fereidoun Azizi, Hadaegh F. No Obesity Paradox—BMI Incapable of Adequately Capturing the Relation of Obesity with All-Cause Mortality: An Inception Diabetes Cohort Study. *International Journal of Endocrinology* Volume 2014 (2014).
102. Khalili D, Haj Sheikholeslami F, Bakhtiyari M, Azizi F, Momenan AA, Hadaegh F. The incidence of coronary heart disease and the population attributable fraction of its risk factors in tehran: a 10-year population-based cohort study. *PLoS One*. 2014 Aug 27;9(8):e105804.
103. Nejat A, Mirbolouk M, Mohebi R, Hasheminia M, Tohidi M, Saadat N, Azizi F, Hadaegh F. Changes in lipid measures and incident coronary heart disease: Tehran Lipid & Glucose Study. *Clin Biochem*. 2014 Sep;47(13-14):1239-44.
104. Ramezankhani A, Pournik O, Shahrabi J, Khalili D, Azizi F, Hadaegh F\*. Applying decision tree for identification of a low risk population for type 2 diabetes. Tehran Lipid and Glucose Study. *Diabetes Res Clin Pract*. 2014 Sep;105(3):391-8.
105. Mohebi R, Mohebi A, Sheikholeslami F, Azizi F, Hadaegh F. Wrist circumference as a novel predictor of hypertension and cardiovascular disease: results of a decade follow up in a West Asian cohort. *J Am Soc Hypertens*. 2014 Nov;8(11):800-7.

106. Jahangiri-Noudeh Y, Akbarpour S, Lotfaliany M, Zafari N, Khalili D, Tohidi M, Mansournia MA, Azizi F, Hadaegh F. Trends in Cardiovascular Disease Risk Factors in People with and without Diabetes Mellitus: A Middle Eastern Cohort Study. *PLoS One*. 2014 Dec 2;9(12):e112639.
107. Derakhshan A, Tohidi M, Arshi B, Khalili D, Azizi F, Hadaegh F\*. Relationship of hyperinsulinaemia, insulin resistance and  $\beta$ -cell dysfunction with incident diabetes and pre-diabetes: the Tehran Lipid and Glucose Study. *Diabet Med*. 2015 Jan;32(1):24-32.
108. Hadaegh F \* S. Ehteshami-Afshar M.A. Hajebrahimi, F. Hajsheikholeslami , F. Azizi. Silent coronary artery disease and incidence of cardiovascular and mortality events at different levels of glucose regulation; results of greater than a decade follow-up. *International Journal of Cardiology* 182 (2015) 334–339
109. Khalili D, Asgari S, Hadaegh F \*, Steyerberg EW, Rahimi K, Fahimfar N, Azizi F. A new approach to test validity and clinical usefulness of the 2013 ACC/AHA guideline on statin therapy: A population-based study. *Int J Cardiol*. 2015 Mar 5;184:587-594.
110. Azimi SS, Khalili D\*, Hadaegh F, Yavari P, Mehrabi Y, Azizi F. Calculating population attributable fraction for cardiovascular risk factors using different methods in a population based cohort study. *J Res Health Sci*. 2015;15(1):22-7.
111. Arshi B, Tohidi M\*, Derakhshan A, Asgari S, Azizi F, Hadaegh F. Sex-specific relations between fasting insulin, insulin resistance and incident hypertension: 8.9 years follow-up in a Middle-Eastern population. *J Hum Hypertens*. 2015 Apr;29(4):260-7. doi: 10.1038/jhh.2014.70. Epub 2014 Aug 28
112. Mirbolouk M1, Asgari S, Sheikholeslami F, Mirbolouk F, Azizi F, Hadaegh F\*. Different obesity phenotypes, and incident cardiovascular disease and mortality events in elderly Iranians: Tehran lipid and glucose study. *Geriatr Gerontol Int*. 2015 Apr;15(4):449-56.
113. Lotfaliany M, Akbarpour S, Mozafary A, Boloukat RR, Azizi F, Hadaegh F\*. Hypertension phenotypes and incident cardiovascular disease and mortality events in a decade follow-up of a Middle East cohort. *Journal of Hypertension*. 2015 Jun;33(6):1153-61.
114. Bahadoran Z, Mirmiran P, Ghasemi A\*, Kabir A, Azizi F, Hadaegh F. Is dietary nitrate/nitrite exposure a risk factor for development of thyroid abnormality? A systematic review and meta-analysis. *Nitric Oxide*. 2015 Apr 15;47:65-76.
115. Navid Saadata, Hadi Esmailyb, Mohammad Abbasinazarib\*, Maryam Tohidia, Jamshid Salamzadehb, Hadaegh F, Maryam Tolabic, Maryam Kalantar- Hormozib and Maryam Dibajc. Does twice-weekly cabergoline improve anthropometrical and biochemical profiles in prediabetes? A randomized double-blind clinical trial pilot study. *Iranian Journal of Pharmaceutical Research*. 2015;14: 77-86.
116. Bahadoran Z, Ghasemi A, Mirmiran P, Azizi F, Hadaegh F\*. Beneficial effects of inorganic nitrate/nitrite in type 2 diabetes and its complications. *Nutr Metab (Lond)*. 2015 May 16;12:16.
117. Ramezankhani A, Pournik O, Shahrabi J, Azizi F, Hadaegh F\*. An application of association rule mining to extract risk pattern for type 2 diabetes using tehran lipid and glucose study database. *Int J Endocrinol Metab*. 2015 Apr 30;13(2):e25389.
118. Mohebi R, Simforoosh A, Tohidi M, Azizi F, Hadaegh F\*. Obesity Paradox and Risk of Mortality Events in Chronic Kidney Disease Patients: A Decade of Follow-up in Tehran Lipid and Glucose Study. *J Ren Nutr*. 2015 Jul;25(4):345-50
119. Hashemi Nazari SS, Shakiba M, Khalili D\*, Hadaegh F, Tohidi M, Azizi F. High-density lipoprotein cholesterol, a protective or a risk factor for developing coronary heart disease? Tehran Lipid and Glucose Study. *J Clin Lipidol*. 2015 Jul-Aug;9(4):553-558.
120. Mousavi SV, Mohebi R, Mozaffary A, Sheikholeslami F, Azizi F, Hadaegh F\*. Changes in body mass index, waist and hip circumferences, waist to hip ratio and risk of all-cause mortality in men. *Eur J Clin Nutr*. 2015 Aug;69(8):927-32.
121. Ghasemi A, Tohidi M, Derakhshan A, Hasheminia M, Azizi F, Hadaegh F. Cut-off points of homeostasis model assessment of insulin resistance, beta-cell function, and fasting serum insulin to identify future type 2 diabetes: Tehran Lipid and Glucose Study. *Acta Diabetol*. 2015 Oct;52(5):905-15.

122. Hadaegh F\*, Hasheminia M, Abdi , Khalili D, Bozorgmanesh M, Arshi B, Azizi F. Prehypertension Tsunami: A Decade Follow-Up of an Iranian Adult Population. *PLoS One*. 2015 Oct 6;10(10):e0139412.
123. Ghoreishian H, Tohidi M\*, Derakhshan A, Hajsheikholeslami F, Azizi F, Kazempour-Ardebili S, Hadaegh F. Presence of hypertension modifies the impact of insulin resistance on incident cardiovascular disease in a Middle Eastern population: the Tehran Lipid and Glucose Study. *Diabet Med*. 2015 Oct;32(10):1311-8.
124. Ayubi E, Khalili D\*, Delpisheh A, Hadaegh F, Azizi F. Factor analysis of metabolic syndrome components and predicting type 2 diabetes: Results of 10-year follow-up in a Middle Eastern population. *J Diabetes*. 2015 Nov;7(6):830-838.
125. Masudi S, Yavari P, Mehrabi Y, Azizi F, Khalili D\*, Hadaegh F. Underestimating the Effect of Lipids on Cardiovascular Events: Regression Dilution Bias in the Population-Based Cohort of Tehran Lipid and Glucose Study. *Int J Endocrinol Metab*. 2015 Oct 3;13(4):e27528.
126. Ramezankhani A, Pournik O, Shahrabi J, Azizi F, Hadaegh F, Khalili D\*. The Impact of Oversampling with SMOTE on the Performance of 3 Classifiers in Prediction of Type 2 Diabetes. *Med Decis Making*. 2016 Jan;36(1):137-44.
127. Bozorgmanesh M, Sardarinia M, Hajsheikholeslami F, Azizi F, Hadaegh F\*. CVD-predictive performances of "a body shape index" versus simple anthropometric measures: Tehran lipid and glucose study. *European journal of nutrition*. 2016 Feb;55(1):147-57.
128. Bagherzadeh-Khiabani F, Ramezankhani A, Azizi F, Hadaegh F, Steyerberg EW, Khalili D.\* A tutorial on variable selection for clinical prediction models: feature selection methods in data mining could improve the results. *Journal of clinical epidemiology*. 2016 Mar;71:76-85.
129. Hadaegh F\*. Derakhshan A, Mozaffary A, Hasheminia M, Khalili D, Azizi F. Twelve-Year Cardiovascular and Mortality Risk in Relation to Smoking Habits in Type 2 Diabetic and Non-Diabetic Men: Tehran Lipid and Glucose Study. *PLoS One*. 2016 Mar 1;11(3):e0149780.
130. Hadaegh F, Asgari S, Bozorgmanesh M, Jeddi S, Azizi F, Ghasemi A\*. Added value of total serum nitrate/nitrite for prediction of cardiovascular disease in middle east caucasian residents in Tehran. *Nitric Oxide*. 2016 Apr 1;54:60-6.
131. Asgari S., Barzin M., Hosseinpanah F\*., Hadaegh F., Azizi F., Khalili D. Obesity Paradox and Risk of Mortality Events in Chronic Kidney Disease Patients: A Decade of Follow-up in Tehran Lipid and Glucose Study. *International Journal of Endocrinology and Metabolism*. Apr 2016. e37018
132. Bahadoran Z, Mirmiran P, Jeddi S, Azizi F, Ghasemi A\*, Hadaegh F. Nitrate and nitrite content of vegetables, fruits, grains, legumes, dairy products, meats and processed meats. *Journal of Food Composition and Analysis*. 2016 Aug;51: 93-105
133. Mozaffary A, Asgari S, Tohidi M, Kazempour-Ardebili S, Azizi F, Hadaegh F\*. Change in fasting plasma glucose and incident type 2 diabetes mellitus: results from a prospective cohort study. *BMJ Open*. 2016 May 23;6(5):e010889.
134. Asgari S, Khalili D, Mehrabi Y, Kazempour-Ardebili S, Azizi F, Hadaegh F\*. Incidence and risk factors of isolated systolic and diastolic hypertension: a 10 year follow-up of the Tehran Lipids and Glucose Study. *Blood Pressure*. 2016 Jun;25(3):177-83.
135. Barkhordari M, Padyab M, Hadaegh F, Azizi F, Bozorgmanesh M\*. Stata Modules for Calculating Novel Predictive Performance Indices for Logistic Models. *Int J Endocrinol Metab*. 2016 Jan 23;14(1):e26707.
136. Ghasemzadeh Z, Abdi H, Asgari S, Tohidi M, Khalili D, Valizadeh M, Moeini S, Eidkhani V, Azizi F, Hadaegh F\*. Divergent pathway of lipid profile components for cardiovascular disease and mortality events: Results of over a decade follow-up among Iranian population. *Nutrition & Metabolism*. 2016 Jun 24;13:43
137. Derakhshan A, Eslami A, Bozorgmanesh M, Sheikholeslami F, Azizi F, Hadaegh F.\* Wrist circumference as a novel negative risk factor for cardiovascular disease among adult men: a median follow-up of 9 years. *Journal of endocrinological investigation*. 2016 Jul;39(7):763-8.

138. Derakhshan A, Bagherzadeh-Khiabani F, Arshi B, Ramezankhani A, Azizi F, Hadaegh F.\* Different Combinations of Glucose Tolerance and Blood Pressure Status and Incident Diabetes, Hypertension, and Chronic Kidney Disease. *J Am Heart Assoc.* 2016 Aug 20;5(8).
139. Ramezankhani A, Kabir A, Pournik O, Azizi F, Hadaegh F.\* Classification-based data mining for identification of risk patterns associated with hypertension in Middle Eastern population: A 12-year longitudinal study. *Medicine (Baltimore).* 2016 Aug;95(35)
140. Afsharian S, Akbarpour S, Abdi H, Sheikholeslami F, Moeini AS, Khalili D, Momenan AA, Azizi F, Hadaegh F.\* Risk factors for cardiovascular disease and mortality events in adults with type 2 diabetes - a 10-year follow-up: Tehran Lipid and Glucose Study. *Diabetes Metab Res Rev.* 2016 Sep;32(6):596-606
141. Panahi MH, Hadaegh F, Yavari P, Kazempour-Ardebili S, Mehrabi Y, Azizi F, Khalili D\* A Challenging Interaction of Chronic Kidney Disease With Other Metabolic Disorders: Paradoxes in Cardiometabolic Risk Factors. *Iranian journal of kidney diseases.* 2016 Sep;10(5):274-281
142. Shaseb E, Tohidi M\*, Abbasiazari M, Khalili D, Talasaz AH, Omrani H, Hadaegh F. The effect of a single dose of vitamin D on glycemic status and C-reactive protein levels in type 2 diabetic patients with ischemic heart disease: a randomized clinical trial. *Acta Diabetol.* 2016 Aug;53(4):575-82.
143. Bahadoran Z, Ghasemi A, Mirmiran P\*, Azizi F, Hadaegh F. Nitrate-nitrite-nitrosamines exposure and the risk of type 1 diabetes: A review of current data. *World J Diabetes.* 2016 Oct 15;7(18):433-440
144. Mirbolouk M, Derakhshan A, Charkhchi P, Guity K, Azizi F, Hadaegh F\*. Incidence and predictors of early adulthood pre-diabetes/type 2 diabetes, among Iranian adolescents: the Tehran Lipid and Glucose Study. *Pediatr Diabetes.* 2016 Dec;17(8):608-616.
145. Ramezankhani A, Hadavandi E, Pournik O, Shahrabi J, Azizi F, Hadaegh F\*. Decision tree-based modelling for identification of potential interactions between type 2 diabetes risk factors: a decade follow-up in a Middle East prospective cohort study. *BMJ Open.* 2016 Dec 1;6(12):e013336.
146. Sardarinia M, Akbarpour S, Lotfaliany M, Bagherzadeh-Khiabani F, Bozorgmanesh M, Sheikholeslami F, Azizi F, Hadaegh F\*. Risk Factors for Incidence of Cardiovascular Diseases and All-Cause Mortality in a Middle Eastern Population over a Decade Follow-up: Tehran Lipid and Glucose Study. *PLoS One.* 2016 Dec 8;11(12):e0167623.
147. Bahadoran Z, Mirmiran P, Ghasemi A, Carlström M, Azizi F, Hadaegh F\*. Vitamin C intake modify the impact of dietary nitrite on the incidence of type 2 diabetes: A 6-year follow-up in Tehran Lipid and Glucose Study. *Nitric Oxide.* 2016 Dec;62:24-31.
148. Bahadoran Z, Mirmiran P\*, Ghasemi A, Carlström M, Azizi F, Hadaegh F.\* Association between Dietary Intakes of Nitrate and Nitrite and the Risk of Hypertension and Chronic Kidney Disease: Tehran Lipid and Glucose Study. *Nutrients.* 2016 Dec 21;8(12)
149. Mirbolouk M, Hajebrahimi MA, Akbarpour S, Tohidi M, Azizi F, Hadaegh F\*. Different glucose tolerance status and incident cardiovascular disease and all-cause mortality among elderly Iranians. *Geriatrics & gerontology international.* 2016 Dec;16(12):1263-1271
150. Barkhordari M, Padyab M, Sardarinia M, Hadaegh F, Azizi F, Bozorgmanesh M\*. Survival Regression Modeling Strategies in CVD Prediction. *Int J Endocrinol Metab.* 2016 Mar 23;14(2):e32156
151. Sardarinia M, Ansari R, Azizi F, Hadaegh F, Bozorgmanesh M\*. Mortality prediction of a body shape index versus traditional anthropometric measures in an Iranian population: Tehran Lipid and Glucose Study. *Nutrition.* 2017 Jan;33:105-112.
152. Eslami A, Mozaffary A, Derakhshan A, Azizi F, Khalili D, Hadaegh F\*. Sex-specific incidence rates and risk factors of premature cardiovascular disease. A long term follow up of the Tehran Lipid and Glucose Study. *Int J Cardiol.* 2017 Jan 15;227:826-832
153. Niroomand M, Hadaegh F, Bahaeddini M, Darvishi N. The 10-year Trend of Adult Diabetes, Prediabetes and Associated Risk Factors in Tehran: Phases 1 and 4 of Tehran Lipid and Glucose Study. *Diabetes Metab Syndr.* Jul-Sep 2017;11(3):183-187.

154. Hadaegh F\*, Derakhshan A, Zafari N, Khalili D, Mirbolouk M, Saadat N, Azizi F. Pre-diabetes tsunami: incidence rates and risk factors of pre-diabetes and its different phenotypes over 9 years of follow-up. *Diabet Med.* 2017 Jan;34(1):69-78.
155. Derakhshan A, Tohidi M\*, Hajebrahimi MA, Saadat N, Azizi F, Hadaegh F. Sex-specific incidence rates and risk factors of insulin resistance and  $\beta$ -cell dysfunction: a decade follow-up in a Middle Eastern population. *Diabet Med.* 2017 Feb;34(2):245-252.
156. Golozar A, Khalili D, Etemadi A, Poustchi H, Fazeltabar A, Hosseini F, Kamangar F, Khoshnia M, Islami F, Hadaegh F, Brennan P, Boffetta P, Abnet CC, Dawsey SM, Azizi F, Malekzadeh R, Danaei G. White rice intake and incidence of type-2 diabetes: analysis of two prospective cohort studies from Iran. *BMC Public Health.* 2017 Jan 31;17(1):133
157. Riyahi-Alam S, Derakhshan A, Mansournia MA, Mansournia N, Almasi M, Azizi F, Hadaegh F.\* Blood pressure and cardiovascular morbidity risk in type 2 diabetes with hypertension over a decade of follow-up: evidence for J-shaped phenomenon. *Journal of Human Hypertension.* 2017 Jun;31(6):415-421
158. Ramezankhani A, Bagherzadeh-Khiabani F, Khalili D, Azizi F, Hadaegh F\*. A new look at risk patterns related to coronary heart disease incidence using survival tree analysis: 12 Years Longitudinal Study. *Sci Rep.* 2017 Jun 12;7(1):3237.
159. Ramezankhani A, Azizi F, Hadaegh F\*, Eskandari F. Sex-specific clustering of metabolic risk factors and their association with incident cardiovascular diseases: A population-based prospective study. *Atherosclerosis.* 2017 Jun 28;263:249-256.
160. Parizadeha D., Ramezankhani A., Momenan AA., Azizi F., Hadaegh F\*. Exploring risk patterns for incident ischemic stroke during more than a decade of follow-up: A survival tree analysis. *Computer Methods and Programs in Biomedicine.* 2017; 147:29-36.
161. Mohammad Ali Mansournia , Kouros Holakouie-Naieni , Noushin Fahimfar , Amir Almasi-Hashiani , Zahra Cheraghi , Erfan Ayubi , Farzad Hadaegh , Fatemeh Eskandari , Fereidoun Azizi and Davood Khalili \*. Risk of Coronary Heart Events Based on Rose Angina Questionnaire and ECG Besides Diabetes and Other Metabolic Risk Factors: Results of a 10-Year Follow-up in Tehran Lipid and Glucose Study. *Int J Endocrinol Metab.* 2017 ;15(2):e42713.
162. Hajebrahimi MA, Akbarpour S, Eslami A, Azizi F, Hadaegh F\*. Different combinations of glucose tolerance and blood pressure status and incident cardiovascular disease and all-cause mortality events. *J Hum Hypertens.* 2017 Nov;31(11):744-749
163. Parizadeh D, Ghahvehchian H, Asgari S, Momenan AA, Azizi F, Hadaegh F\*. The association between changes in blood pressure components and incident cardiovascular diseases. *Blood Press.* 2017 Dec;26(6):341-349.
164. Ramezankhani A, Azizi F, Ghanbarian A, Parizadeh D, Hadaegh F\*. The hypertriglyceridemic waist and waist-to-height ratio phenotypes and chronic kidney disease: Cross-sectional and prospective investigations. *Obes Res Clin Pract.* 2017 Sep - Oct;11(5):585-596.
165. Abdi H\*, Hosseinpanah F, Azizi F, Hadaegh F, Amouzegar A. Screening for Dysglycemia: A Comment on Classification and Diagnosis of Diabetes in American Diabetes Association Standards of Medical Care in Diabetes-2016. *Arch Iran Med.* 2017 Jun;20(6):389. Editorial Material
166. Gilani N\*, Kazemnejad A, Zayeri F, Hadaegh F, Azizi F, Khalili D. Anthropometric Indices as Predictors of Coronary Heart Disease Risk: Joint Modeling of Longitudinal Measurements and Time to Event. *Iranian Journal of Public Health.* 2017 Nov;46(11):1546-1554.
167. Taravatmanesh S, Khalili D, Khodakarim S, Asgari S, Hadaegh F, Azizi F, Sabour S\*. Determining the Factors Associated with Cardiovascular Disease Recurrence: Tehran Lipid and Glucose Study. *J Tehran Heart Cent.* 2017 Jul;12(3):107-113.
168. Kalantari S, Khalili D\*, Asgari S, Fahimfar N, Hadaegh F, Tohidi M, Azizi F. Predictors of early adulthood hypertension during adolescence: a population-based cohort study. *BMC Public Health.* 2017 Nov 28;17(1):915.

169. Ramezankhani A, Tohidi M, Azizi F, Hadaegh F.\* Application of survival tree analysis for exploration of potential interactions between predictors of incident chronic kidney disease: a 15-year follow-up study. *Journal of translational medicine*. 2017 Nov 28;15(1):240.
170. Zafari N, Asgari S, Lotfaliany M, Hadaegh A, Azizi F, Hadaegh F\*. Impact Of Hypertension versus Diabetes on Cardiovascular and All-cause Mortality in Iranian Older Adults: Results of 14 Years of Follow-up. *Sci Rep*. 2017 Oct 27;7(1):14220.
171. Kazempour-Ardebili S, Ramezankhani A, Eslami A, Akbarpour S, Azizi F, Hadaegh F\*. Metabolic mediators of the impact of general and central adiposity measures on cardiovascular disease and mortality risks in older adults: Tehran Lipid and Glucose Study. *Geriatrics & gerontology international*. *Geriatr Gerontol Int*. 2017 Nov;17(11):2017-2024.
172. Collaborators (1040). Worldwide trends in body-mass index, underweight, overweight, and obesity from 1975 to 2016: a pooled analysis of 2416 population-based measurement studies in 128·9 million children, adolescents, and adults. *Lancet*. 2017 Dec 16;390(10113):2627-2642.
173. Zameni F, Bakhtiyari M, Mansournia MA, Ramezankhani A, Azizi F, Hadaegh F\*. Is incident type 2 diabetes associated with cumulative excess weight and abdominal adiposity? Tehran Lipid and Glucose Study. *Diabetes Res Clin Pract*. 2017 Dec 8;136:134-142.
174. Eslami A, Lotfaliany M, Akbarpour S, Azizi F, Hadaegh F\*. Trend of cardiovascular risk factors in the older Iranian population: 2002-2014. *Geriatr Gerontol Int*. 2018 Jan;18(1):130-137
175. Tohidi M, Derakhshan A, Akbarpour S, Amouzegar A, Mehran L, Baghbani-Oskouei A, Azizi F, Hadaegh F\*. Thyroid Dysfunction States and Incident Cardiovascular Events: The Tehran Thyroid Study. *Horm Metab Res*. 2018 Jan;50(1):37-43.
176. Kabootari M, Asgari S, Mansournia MA, Khalili D, Valizadeh M, Azizi F, Hadaegh F\*. Different Weight Histories and Risk of Incident Coronary Heart Disease and Stroke: Tehran Lipid and Glucose Study. *J Am Heart Assoc*. 2018 Feb 10;7(4).
177. Bahadoran Z, Carlström M, Ghasemi A, Mirmiran P\*, Azizi F, Hadaegh F. Total antioxidant capacity of the diet modulates the association between habitual nitrate intake and cardiovascular events: A longitudinal follow-up in Tehran Lipid and Glucose Study. *Nutr Metab (Lond)*. 2018 Feb 27;15:19.
178. Ramezankhani A, Azizi F, Hadaegh F\*, Momenan AA. Diabetes and number of years of life lost with and without cardiovascular disease: a multi-state homogeneous semi-Markov model. *Acta Diabetol*. 2018 Mar;55(3):253-262.
179. Rabani S, Sardarinia M, Akbarpour S, Azizi F, Khalili D, Hadaegh F\*. 12-year trends in cardiovascular risk factors (2002-2005 through 2011-2014) in patients with cardiovascular diseases: Tehran lipid and glucose study. *PLoS One*. 2018 May 16;13(5):e0195543.
180. Zafari N, Lotfaliany M, Mansournia MA, Khalili D, Azizi F, Hadaegh F\*. Optimal cut-points of different anthropometric indices and their joint effect in prediction of type 2 diabetes: results of a cohort study. *BMC Public Health*. 2018 Jun 5;18(1):691.
181. Fahimfar N, Khalili D, Sepanlou SG, Malekzadeh R\*, Azizi F, Mansournia MA, Roohafza H, Emamian MH, Hadaegh F, Poustchi H, Mansourian M, Hashemi H, Sharafkhan M, Pourshams A, Farzadfar F, Steyerberg EW, Fotouhi A. Cardiovascular mortality in a Western Asian country: results from the Iran Cohort Consortium. *BMJ Open*. 2018 Jul 5;8(7):e020303.
182. Khaloo P, Hasheminia M, Tohidi M, Abdi H, Mansournia MA, Azizi F, Hadaegh F.\* Impact of 3-year changes in lipid parameters and their ratios on incident type 2 diabetes: Tehran lipid and glucose study. *Nutr Metab (Lond)*. 2018 Jul 11;15:50.
183. Bakhtiyari M, Schmidt N, Hadaegh F, Khalili D, Mansournia N, Asgari S, Mansournia MA.\* Direct and indirect effects of central and general adiposity on cardiovascular diseases: The Tehran Lipid and Glucose Study. *Eur J Prev Cardiol*. 2018 Jul;25(11):1170-1181.
184. Hashemi A, Nourbakhsh S, Asgari S, Mirbolouk M, Azizi F, Hadaegh F\*. Blood pressure components and incident cardiovascular disease and mortality events among Iranian adults with chronic kidney disease during over a decade long follow-up: a prospective cohort study. *J Transl Med*. 2018 Aug 15;16(1):230.

185. Tohidi M, Baghbani-Oskouei A, Ahanchi NS, Azizi F, Hadaegh F\*. Fasting plasma glucose is a stronger predictor of diabetes than triglyceride-glucose index, triglycerides/high-density lipoprotein cholesterol, and homeostasis model assessment of insulin resistance: Tehran Lipid and Glucose Study. *Acta Diabetol.* 2018 Oct;55(10):1067-1074.
186. Boloukat RR, Ramezankhani A, Hasheminia M, Tasdighi E, Azizi F, Hadaegh F.\* Impact of blood pressure, cholesterol and glucose in the association between adiposity measures and coronary heart disease and stroke among Iranian population. *Clin Nutr.* 2018 Dec;37(6 Pt A):2060-2067.
187. Ghasemi A, Asgari S, Hadaegh F, Kheirandish M, Azimzadeh I, Azizi F, Tohidi M\*. New modified Friedewald formulae for estimating low-density lipoprotein cholesterol according to triglyceride levels: extraction and validation. *Endocrine.* 2018 Nov;62(2):404-411.
188. Ramezankhani A, Ehteshami-Afshar S, Hasheminia M, Hajebrahimi MA, Azizi F, Hadaegh F\*. Optimum cutoff values of anthropometric indices of obesity for predicting hypertension: more than one decades of follow-up in an Iranian population. *J Hum Hypertens.* 2018 Dec;32(12):838-848.
189. Hashemi A, Nourbakhsh S, Asgari S, Mirbolouk M, Azizi F, Hadaegh F\*. Blood pressure components and incident cardiovascular disease and mortality events among Iranian adults with chronic kidney disease during over a decade long follow-up: a prospective cohort study. *J Transl Med.* 2018 Aug 15;16(1):230.
190. Kabootari M, Raei MR, Akbarpour S, Asgari S, Azizi F, Hadaegh F\*. Serum alkaline phosphatase and the risk of coronary heart disease, stroke and all-cause mortality: Tehran Lipid and Glucose Study. *BMJ Open.* 2018 Nov 25;8(11):e023735.
191. Salehinia F, Abdi H, Hadaegh F, Serahati S, Valizadeh M, Azizi F, Hosseinpanah F\*. Abdominal obesity phenotypes and incident diabetes over 12 years of follow-up: The Tehran Lipid and glucose study. *Diabetes Res Clin Pract.* 2018 Oct;144:17-2
192. Ramezankhani A, Harati H, Bozorgmanesh M, Tohidi M, Khalili D, Azizi F, Hadaegh F.\* Diabetes Mellitus: Findings from 20 Years of the Tehran Lipid and Glucose Study. *Int J Endocrinol Metab.* 2018 Oct 16;16(4 Suppl):e84784.
193. Abdi H, Amouzegar A, Tohidi M, Azizi F, Hadaegh F\*. Blood Pressure and Hypertension: Findings from 20 Years of the Tehran Lipid and Glucose Study (TLGS). *Int J Endocrinol Metab.* 2018 Oct 20;16(4 Suppl):e84769.
194. Baghbani-Oskouei A, Tohidi M\*, Asgari S, Ramezankhani A, Azizi F, Hadaegh F. Serum Lipids During 20 Years in the Tehran Lipid and Glucose Study: Prevalence, Trends and Impact on Non-Communicable Diseases. *Int J Endocrinol Metab.* 2018 Oct 16;16(4 Suppl):e84750.
195. Parizadeh D, Momenan AA, Amouzegar A, Azizi F, Hadaegh F\*. Tobacco Smoking: Findings from 20 Years of the Tehran Lipid and Glucose Study. *Int J Endocrinol Metab.* 2018 Oct 31;16(4 Suppl):e84738.
196. Khalili D, Azizi F\*, Asgari S1, Zadeh-Vakili A, Momenan AA, Ghanbarian A, Eskandari F, Sheikholeslami F, Hadaegh F. Outcomes of a Longitudinal Population-based Cohort Study and Pragmatic Community Trial: Findings from 20 Years of the Tehran Lipid and Glucose Study.
197. Lotfaliany M, Akbarpour S, Zafari N, Mansournia MA, Asgari S, Azizi F, Hadaegh F, Khalili D\*. World Bank Income Group, Health Expenditure or Cardiometabolic Risk Factors? A Further Explanation of the Wide Gap in Cardiometabolic Mortality Between Worldwide Countries: An Ecological Study. *Int J Endocrinol Metab.* 2018 Jul 10;16(3):e59946.
198. Talasaz AH, Shaseb E, Tohidi M, Hadaegh F, Ariannejad H, Abbasinazari M\*. Effects of Parenteral Vitamin D on the Biomarkers of the Endothelial Function in Patients with Type 2 Diabetes and Ischemic Heart Disease: A Randomized Clinical Trial. *Iran J Pharm Res.* 2018;17(Suppl2):187-194.
199. Khajavi A., Khalili D., Azizi F., Hadaegh F.\* Impact of temperature and air pollution on cardiovascular disease and death in Iran: A 15-year follow-up of Tehran Lipid and Glucose Study. *Science of the Total Environment.* 2019 Apr; 661:243-250.
200. Collaborators (178). Hadaegh F. Adiposity and risk of decline in glomerular filtration rate: meta-analysis of individual participant data in a global consortium. *BMJ.* 2019 Jan 10;364:k5301.

201. Ahanchi NS, Hadaegh F, Alipour A, Ghanbarian A, Azizi F, Khalili D\*. Application of Latent Class Analysis to Identify Metabolic Syndrome Components Patterns in adults: Tehran Lipid and Glucose study. *Sci Rep.* 2019 Feb 7;9(1):1572.
202. Khalili D, Asgari S, Lotfaliany M, Zafari N, Hadaegh F, Momenan AA, Nowroozpoor A, Hosseini-Esfahani F, Mirmiran P, Amiri P, Azizi F\*. Long-Term Effectiveness of a Lifestyle Intervention: A Pragmatic Community Trial to Prevent Metabolic Syndrome. *Am J Prev Med.* 2019 Mar;56(3):437-446.
203. Bahadoran Z, Ghasemi A, Mirmiran P\*, Mehrabi Y, Azizi F, Hadaegh F. Estimation and Validation of Dietary Nitrate and Nitrite Intake in Iranian Population. *Iran J Public Health.* 2019 Jan; 48(1): 162-170
204. Kabootari M, Akbarpour S, Azizi F, Hadaegh F\*. Sex specific impact of different obesity phenotypes on the risk of incident hypertension: Tehran lipid and glucose study. *Nutr Metab (Lond).* 2019 Feb 27;16:16.
205. Asgari S, Khaloo P, Khalili D, Azizi F, Hadaegh F\*. Status of Hypertension in Tehran: Potential impact of the ACC/AHA 2017 and JNC7 Guidelines, 2012-2015. *Sci Rep.* 2019 Apr 23;9(1):6382.
206. Ramezankhani A, Azizi F, Hadaegh F\*. Associations of marital status with diabetes, hypertension, cardiovascular disease and all-cause mortality: A long term follow-up study. *PLoS One.* 2019 Apr 22;14(4):e0215593.
207. Ahanchi NS, Ramezankhani A, Munthali RJ, Asgari S, Azizi F, Hadaegh F\*. Body mass index trajectories from adolescent to young adult for incident high blood pressure and high plasma glucose. *PLoS One.* 2019 May 1;14(5):e0213828.
208. Amiri P, Vahedi-Notash G, Naseri P, Khalili D, Hashemi Nazari SS, Mehrabi Y, Mahdavi Hazaveh AR, Azizi F, Hadaegh F\*. National trends of pre-hypertension and hypertension among Iranian adolescents across urban and rural areas (2007-2011). *Biol Sex Differ.* 2019 Mar 29;10(1):15.
209. NCD Risk Factor Collaboration (NCD-RisC). Rising rural body-mass index is the main driver of the global obesity epidemic in adults. *Nature.* 2019 May;569(7755):260-264. LETTER
210. Lotfaliany M, Hadaegh F, Asgari S, Mansournia MA, Azizi F, Oldenburg B, Khalili D\*. Non-invasive Risk Prediction Models in Identifying Undiagnosed Type 2 Diabetes or Predicting Future Incident Cases in the Iranian Population. *Arch Iran Med.* 2019 Mar 1;22(3):116-124.
211. Parizadeh D, Rahimian N, Akbarpour S, Azizi F, Hadaegh F\*. Sex-specific clinical outcomes of impaired glucose status: A long follow-up from the Tehran Lipid and Glucose Study. *Eur J Prev Cardiol.* 2019 Jul;26(10):1080-1091.
212. Eslami A, Naghibi Irvani SS, Ramezankhani A, Fekri N, Asadi K, Azizi F, Hadaegh F\*. Incidence and associated risk factors for premature death in the Tehran Lipid and Glucose Study cohort, Iran. *BMC Public Health.* 2019 Jun 10;19(1):719
213. Kabootari M, Hasheminia M, Guity K, Ramezankhani A, Azizi F, Hadaegh F\*. Gestational diabetes mellitus in mothers and long term cardiovascular disease in both parents: Results of over a decade follow-up of the Iranian population. *Atherosclerosis.* 2019 Jul 18;288:94-100.
214. Amiri P, Mohammadzadeh-Naziri K, Abbasi B, Cheraghi L, Jalali-Farahani S, Momenan AA, Amouzegar A\*, Hadaegh F, Azizi F. Smoking habits and incidence of cardiovascular diseases in men and women: findings of a 12 year follow up among an urban Eastern-Mediterranean population. *BMC Public Health.* 2019 Aug 5;19(1):1042.
215. Ramezankhani A, Guity K, Azizi F, Hadaegh F\*. Sex differences in the association between spousal metabolic risk factors with incidence of type 2 diabetes: a longitudinal study of the Iranian population. *Biology of Sex Differences.* 2019 Aug 22;10(1):41.
216. Azizi F, Hadaegh F, Hosseinpanah F, Mirmiran P, Amouzegar A, Abdi H, Asghari G, Parizadeh D, Montazeri SA, Lotfaliany M, Takyar F, Khalili D\*. Metabolic health in the Middle East and north Africa. *Lancet Diabetes Endocrinol.* 2019 Aug 14.
217. Kolifarhood G, Daneshpour M, Hadaegh F, Sabour S, Mozafar Saadati H, Akbar Haghdoost A, Akbarzadeh M, Sedaghati-Khayat B, Khosravi N. Heritability of blood pressure traits in diverse populations: a systematic review and meta-analysis. *J Hum Hypertens.* 2019 Sep 24



218. Eidkhani V, Parizadeh D, Hasheminia M, Azizi F, Hadaegh F\*. Impaired fasting glucose prevalence surge among Iranian adolescents in a decade: The Tehran Lipid and Glucose Study. *Pediatr Diabetes*. 2019 Dec;20(8):1064-1071.
219. Parizadeh D, Moazzeni SS, Hasheminia M, Khaloo P, Mansournia MA, Azizi F, Momenan AA, Hadaegh F\*. Sex-specific initiation rates of tobacco smoking and its determinants among adults from a Middle Eastern population: a cohort study. *Int J Public Health*. 2019 Dec;64(9):1345-1354
220. Baghbani-Oskouei A, Tohidi M\*, Hasheminia M, Azizi F, Hadaegh F. Impact of 3-year changes in fasting insulin and insulin resistance indices on incident hypertension: Tehran lipid and glucose study. *Nutr Metab (Lond)*. 2019 Nov 9;16:76.
221. Behboudi-Gandevani S, Abedini M, Soleymani-Dodaran M, Khalili D, Farzadfar F, Hoseinpanah F, Hadaegh F, Valizadeh M, Torkestani F, Abdollahi Z, Bakhshandeh M, Bidhendi Yarandi R, Zokaee M, Bidarpour F, Javanbakht M, Nabipour I, Mansournia MA, Nasli Esfahani E, Ostovar A, Azizi F, Najari A, Khajeian A, Anaraki A, Ghazaghi F, Lahouni F, Kalantari F, Fallah H, Kordi K, Saed L, Noroozadeh M, Farahmand M, Rostami Dovom M, Hedayati M, Mehdizade M, Amiri M, Lotfi MH, Motlagh ME, Bashghareh M, Zamanipour N, Mirmiran P, Sadeghian Sharif S, Shahraz S, Khari S, Alishahi S, Shahgheibi S, Nazarpour S, Mehrabi Y, Ghaedmohammadi Z. Cost effectiveness of different screening strategies for gestational diabetes mellitus screening: study protocol of a randomized community non-inferiority trial. *Diabetol Metab Syndr*. 2019 Dec 18;11:106.
222. Farrokhian A, Tohidi M\*, Ahanchi NS, Khalili D, Niroomand M, Mahboubi A, Derakhshi A, Abbasinazari M, Hadaegh F. Effect of Bedtime Melatonin Administration in Patients With Type 2 Diabetes: A Triple-Blind, Placebo-Controlled, Randomized Trial. *Iranian Journal of Pharmaceutical Research*. 2019. 18: 258-268.
223. Fekri N, Khaloo P, Ramezankhani A, Mansournia MA, Azizi F, Hadaegh F\*. Association of body mass index with life expectancy with and without cardiovascular disease. *Int J Obes (Lond)*. 2020 Jan;44(1):195-203.
224. Hadaegh F, Asgari S, Hashemi P, Baghbani-Oskouei A, Eskandari F, Azizi F, Tohidi M\*. All-cancer incidence in Tehranian adults: more than a decade of follow-up-results from the Tehran Lipid and Glucose Study. *Public Health*. 2020 Feb 20;181:189-195.
225. Ramezankhani A, Guity K, Azizi F, Hadaegh F\*. Spousal metabolic risk factors and incident hypertension: A longitudinal cohort study in Iran. *J Clin Hypertens (Greenwich)*. 2020 Jan;22(1):95-102.
226. Ramezankhani A, Guity K, Azizi F, Hadaegh F\*. Spousal metabolic risk factors and future cardiovascular events: A prospective cohort study. *Atherosclerosis*. 2020 Mar 3;298:36-41
227. Baghfalaki T\*, Kalantari S, Ganjali M, Hadaegh F, Pahlavanzadeh B. Bayesian joint modeling of ordinal longitudinal measurements and competing risks survival data for analysing Tehran Lipid and Glucose Study. *J Biopharm Stat*. 2020 Mar 4:1-15
228. Kabootari M, Hasheminia M, Azizi F, Mirbolouk M, Hadaegh F\*. Change in glucose intolerance status and risk of incident cardiovascular disease: Tehran Lipid and Glucose Study. *Cardiovasc Diabetol*. 2020 Mar 30;19(1):41.
229. Ramezankhani A, Azizi F, Hadaegh F\*. Sex-specific clustering of metabolic risk factors and cancer risk: a longitudinal study in Iran. *Biol Sex Differ*. 2020 Apr 25;11(1):21.
230. Asgari S, Lotfaliany M, Fahimfar N, Hadaegh F, Azizi F, Khalili D\*. The external validity and performance of the no-laboratory American Diabetes Association screening tool for identifying undiagnosed type 2 diabetes among the Iranian population. *Prim Care Diabetes*. 2020 Jun 7:S1751-9918(20)30167-4.
231. NCD Risk Factor Collaboration (NCD-RisC). Repositioning of the global epicentre of non-optimal cholesterol. *Nature*. 2020 Jun;582(7810):73-77.
232. Asgari S, Moazzeni SS, Azizi F, Abdi H, Khalili D, Hakemi MS, Hadaegh F\*. Sex-Specific Incidence Rates and Risk Factors for Hypertension During 13 Years of Follow-up: The Tehran Lipid and Glucose Study. *Glob Heart*. 2020 Apr 8;15(1):29.

233. Ramezankhani A, Blaha MJ, Mirbolouk MH, Azizi F, Hadaegh F\*. Multi-state analysis of hypertension and mortality: application of semi-Markov model in a longitudinal cohort study. *BMC Cardiovasc Disord*. 2020 Jul 6;20(1):321.
234. Asgari S, Moosaie F, Khalili D, Azizi F, Hadaegh F\*. External validation of the European risk assessment tool for chronic cardio-metabolic disorders in a Middle Eastern population. *Journal of Translational Medicine*. 2020 Jul 2;18(1):267.
235. Malekzadeh H, Lotfaliany M, Ostovar A, Hadaegh F, Azizi F, Yoosefi M, Farzadfar F, Khalili D\*. Trends in cardiovascular risk factors in diabetic patients in comparison to general population in Iran: findings from National Surveys 2007-2016. *Sci Rep*. 2020 Jul 16;10(1):11724.
236. Lotfaliany M, Mansournia MA, Azizi F, Hadaegh F, Zafari N, Ghanbarian A, Mirmiran P, Oldenburg B, Khalili D\*. Long-term effectiveness of a lifestyle intervention on the prevention of type 2 diabetes in a middle-income country. *Sci Rep*. 2020 Aug 25;10(1):14173.
237. Malek M, Hosseinpanah F, Aghaei Meybodi HR, Jahed SA, Hadaegh F, Sharghi S, Esteghamati A, Khamseh ME\*. Diabetes Management during the COVID-19 Pandemic: An Iranian Expert Opinion Statement. *Arch Iran Med*. 2020 Aug 1;23(8):564-567.
238. Barzegar N, Tohidi M\*, Hasheminia M, Azizi F, Hadaegh F. The impact of triglyceride-glucose index on incident cardiovascular events during 16 years of follow-up: Tehran Lipid and Glucose Study. *Cardiovasc Diabetol*. 2020 Sep 29;19(1):155.
239. Moazzeni SS, Ghafelehbashi H, Hasheminia M, Parizadeh D, Ghanbarian A, Azizi F, Hadaegh F\*. Sex-specific prevalence of coronary heart disease among Tehranian adult population across different glycemic status: Tehran lipid and glucose study, 2008-2011. *BMC Public Health*. 2020 Oct 6;20(1):1510.
240. Ramezankhani A, Azizi F, Hadaegh F\*. Sex Differences in Rates of Change and Burden of Metabolic Risk Factors Among Adults Who Did and Did Not Go On to Develop Diabetes: Two Decades of Follow-up From the Tehran Lipid and Glucose Study. *Diabetes Care*. 2020 Oct 5:dc201112. EPUB
241. Matsushita K, Jassal SK, Sang Y, Ballew SH, Grams ME, Surapaneni A, Arnlov J, Bansal N, Bozic M, Brenner H, Brunskill NJ, Chang AR, Chinnadurai R, Cirillo M, Correa A, Ebert N, Eckardt KU, Gansevoort RT, Gutierrez O, Hadaegh F, He J, Hwang SJ, Jafar TH, Kayama T, Kovesdy CP, Landman GW, Levey AS, Lloyd-Jones DM, Major RW, Miura K, Muntner P, Nadkarni GN, Naimark DM, Nowak C, Ohkubo T, Pena MJ, Polkinghorne KR, Sabanayagam C, Sairenchi T, Schneider MP, Shalev V, Shlipak M, Solbu MD, Stempniewicz N, Tollitt J, Valdivielso JM, van der Leeuw J, Wang AY, Wen CP, Woodward M, Yamagishi K, Yatsuya H, Zhang L, Schaeffner E, Coresh J. Incorporating kidney disease measures into cardiovascular risk prediction: Development and validation in 9 million adults from 72 datasets. *EClinicalMedicine*. 2020 Oct 14;27:100552.
242. Valizadeh M, Hosseinpanah F, Tehrani FR, Abdi H, Mehran L, Hadaegh F, Amouzegar A, Sarvghadi F, Azizi F, Force IE. Iranian Endocrine Society Guidelines for Screening, Diagnosis, and Management of Gestational Diabetes Mellitus. *International Journal of Endocrinology and Metabolism*. 2020 Dec 23;19(1):e107906.
243. Amiri P, Naseri P, Vahedi-Notash G, Jalali-Farahani S, Mehrabi Y, Hamzavi-Zarghani N, Azizi F, Hadaegh F, Khalili D\*. Trends of low physical activity among Iranian adolescents across urban and rural areas during 2006-2011. *Sci Rep*. 2020 Dec 7;10(1):21318.
244. Bashash D\*, Olfatifar M, Hadaegh F, Asadzadeh Aghdai H, Zali MR. COVID-19 prognosis: what we know of the significance and prognostic value of liver-related laboratory parameters in SARS-CoV-2 infection. *Gastroenterol Hepatol Bed Bench*. 2020 Fall;13(4):313-320.
245. NCD Risk Factor Collaboration (NCD-RisC). Hadaegh F. Height and body-mass index trajectories of school-aged children and adolescents from 1985 to 2019 in 200 countries and territories: a pooled analysis of 2181 population-based studies with 65 million participants. *Lancet*. 2020 Nov 7;396(10261):1511-1524.
246. Zahedi M, Hizomi Arani R, Tohidi M, Haghighi S, Mehrpour M, Hadaegh F\*. Nasopharyngeal B-cell lymphoma with pan-hypopituitarism and oculomotor nerve palsy: a case report and review of the literature. *BMC Endocr Disord*. 2020 Nov 3;20(1):163.

247. Asghari G, Hasheminia M, Heidari A, Mirmiran P, Guity K, Shahrzad MK, Azizi F, Hadaegh F\*. Adolescent metabolic syndrome and its components associations with incidence of type 2 diabetes in early adulthood: Tehran lipid and glucose study. *Diabetol Metab Syndr*. 2021 Jan 2;13(1):1.
248. Hadaegh F\*, Asgari S, Moosaie F, Orangi M, Sarvghadi F, Khalili D, Azizi F. The risk and added values of the atherosclerotic cardiovascular risk enhancers on prediction of cardiovascular events: Tehran lipid and glucose study. *J Transl Med*. 2021 Jan 6;19(1):25.

249. Moazzeni SS, Toreyhi H, Asgari S, Azizi F, Tehrani FR, Hadaegh F.\* Number of parity/live birth(s) and cardiovascular disease among Iranian women and men: results of over 15 years of follow-up. *BMC Pregnancy Childbirth*. 2021 Jan 7;21(1):28.
250. Rahmani F, Asgari S, Khalili D, Habibi Moeini AS, Tohidi M, Azizi F, Hadaegh F.\* National trends in cardiovascular health metrics among Iranian adults using results of three cross-sectional STEPwise approaches to surveillance surveys. *Sci Rep*. 2021 Jan 8;11(1):58.
251. Tohidi M, Baghbani-Oskouei A, Amouzegar A, Mehran L, Azizi F, Hadaegh F.\* Serum Thyroid Peroxidase Antibody Level and Incident Hypertension in Iranian Men: A Suggestion for the Role of Thyroid Autoimmunity. *Endocr Metab Immune Disord Drug Targets*. 2020;20(10):1711-1718.
252. Ramezankhani A, Hosseini-Esfahani F\*, Mirmiran P, Azizi F, Hadaegh F. The association of priori and posteriori dietary patterns with the risk of incident hypertension: Tehran Lipid and Glucose Study. *J Transl Med*. 2021 Jan 25;19(1):44.
253. Rahmani F, Tohidi M, Dehghani M, Broumand B, Hadaegh F.\* Recurrence of a neuroendocrine tumor of adrenal origin: a case report with more than a decade follow-up. *BMC Endocr Disord*. 2021 Jan 7;21(1):9.
254. Fekri N, Hadaegh F, Ramezankhani A, Mansournia MA\*. The protective effect of obesity on mortality among those with (or without) CVD cannot be fully explained by collider-stratification bias. *Int J Obes (Lond)*. 2021 Feb 2.
255. Ahanchi NS, Tamehri Zadeh SS, Khalili D, Azizi F, Hadaegh F.\* Sex specific trajectories of central adiposity, lipid indices, and glucose level with incident hypertension: 12 years Follow-up in Tehran lipid and glucose study. *J Transl Med*. 2021 Feb 23;19(1):84
256. NCD Risk Factor Collaboration. Dr. Hadegh- Dr. Khalili. Heterogeneous contributions of change in population distribution of body mass index to change in obesity and underweight. *Elife*. 2021 Mar 9;10:e60060.
257. Erfanpoor S, Etemad K, Kazempour S, Hadaegh F, Hasani J, Azizi F, Parizadeh D, Khalili D\*. Diabetes, Hypertension, and Incidence of Chronic Kidney Disease: Is There any Multiplicative or Additive Interaction?. *International Journal of Endocrinology and Metabolism*. 2021 Jan 31;19(1).
258. Khajavi A, Zadeh SS, Azizi F, Brook RD, Abdi H, Zayeri F, Hadaegh F\*. Impact of short-and long-term exposure to air pollution on blood pressure: A two-decade population-based study in Tehran. *International Journal of Hygiene and Environmental Health*. 2021 May 1;234:113719.
259. Hadaegh F\*, Asgari S, Toreyhi H, Eskandari F, Fahimfar N, Bozorgmanesh M, Hosseinpanah F, Azizi F. Sex-specific incidence rates and risk factors for fracture: A 16-year follow-up from the Tehran lipid and glucose study. *Bone*. 2021 May 1;146:115869.
260. Moazzeni SS, Arani RH, Hasheminia M, Tohidi M, Azizi F, Hadaegh F\*. High Incidence of Chronic Kidney Disease among Iranian Diabetic Adults: Using CKD-EPI and MDRD Equations for Estimated Glomerular Filtration Rate. *Diabetes and Metabolism Journal*. 2021 Mar 16. E PUB
261. Khajavi A, Zayeri F, Ramezankhani A, Nazari A, Azizi F, Hadaegh F\*. Age and aging effects on blood pressure: 15 years follow-up of Tehran lipid and glucose study. *J Clin Hypertens (Greenwich)*. 2021 Mar 15.
262. Kolifarhood G, Daneshpour MS, Zahedi AS, Khosravi N, Sedaghati-Khayat B, Guity K, Rasekhi Dehkordi S, Amiri Roudbar M, Ghanbari F, Hadaegh F, Azizi F, Akbarzadeh M.\* Familial genetic and environmental risk profile and high blood pressure event: a prospective cohort of cardio-metabolic and genetic study. *Blood Pressure*. 2021 Mar 31:1-9.
263. Amouzegar A, Asgari S, Azizi F, Momenan AA, Bozorgmanesh M, Hadaegh F.\* The Role of Metabolic Syndrome and its Components in Incident Fracture: A 15-Year Follow-Up Among the Iranian Population. *J Clin Endocrinol Metab*. 2021 Apr 23;106(5):e1968-e1983.
264. Vahidi M, Asgari S, Tohidi M\*, Azizi F, Hadaegh F. Macrosomia is a risk factor for incident maternal chronic kidney disease. *BMC Pregnancy Childbirth*. 2021 Mar 16;21(1):210.
265. Barzegar N, Tohidi M\*, Ghodssi-Ghassemabadi R, Amiri P, Azizi F, Hadaegh F. Impact of educational level on incident chronic kidney disease during 13 years of follow-up: a prospective cohort study. *Public Health*. 2021 May 30;195:98-104.
266. Kolifarhood G, Sabour S, Akbarzadeh M, Sedaghati-Khayat B, Guity K, Rasekhi Dehkordi S, Amiri Roudbar M, Hadaegh F, Azizi F, Daneshpour MS\*. Genome-wide association study on blood pressure traits in the Iranian population suggests ZBED9 as a new locus for hypertension. *Sci Rep*. 2021 Jun 3;11(1):11699.
267. Lotfaliany M, Hadaegh F, Mansournia MA, Azizi F, Oldenburg B, Khalili D\*. Performance of Stepwise Screening Methods in Identifying Individuals at High Risk of Type 2 Diabetes in an Iranian

287. Sardarinia M, Asgari S, Hizomi Arani R, Eskandari F, Azizi F, Khalili D, Hadaegh F\*. Incidence and risk factors of severe non-proliferative/proliferative diabetic retinopathy: More than a decade follow-up in Tehran Lipids and Glucose Study. *Journal of Diabetes Investigation*. 2022 Feb;13(2):317-327
288. Ramezankhani A, Parizadeh D, Azizi F, Hadaegh F\*. Sex differences in the association between diabetes and hypertension and the risk of stroke: cohort of the Tehran Lipid and Glucose Study. *Biol Sex Differ*. 2022 Mar 15;13(1)
289. Tohidi M, Barzegar N\*, Hasheminia M, Azizi F, Hadaegh F\*. Association of different lipid measures with incident bone fractures: Tehran lipid and glucose study. *Postgrad Med*. 2022 Apr;134(3):326-332
290. Tamehri Zadeh SS, Moazzeni SS, Matsushita K, Hasheminia M, Azizi F, Hadaegh F\*. Application of the 2017 American college of cardiology/American Heart Association Blood Pressure Guidelines for cardiovascular outcomes among Tehranian residents. *J Hypertens*. 2022 Feb
291. Fahimfar N, Malekzadeh R, Fotouhi A\*, Mansournia MA, Sarrafzadegan N, Azizi F, Sepanlou SG, Mansourian M, Hadaegh F, Emamian MH, Poustchi H, Talaei M, Pourshams A, Roohafza H, Sharafkhah M, Samavat T, Lotfaliany M, Steyerberg EW, Khalili D. An office-based cardiovascular prediction model developed and validated in cohort studies of a middle-income country. *J Clin Epidemiol*. 2022 Dec 14.
292. Hosseinpour-Niazi S, Mirmiran P\*, Hadaegh F, Mahdavi M, Khalili D, Daneshpour MS, Momenan AA, Azizi F. Improvement of glycemic indices by a hypocaloric legume-based DASH diet in adults with type 2 diabetes: a randomized controlled trial. *Eur J Nutr*. 2022 Mar 26
293. Fahimfar N, Fotouhi A, Mansournia MA, Malekzadeh R, Sarrafzadegan N, Azizi F, Mansourian M, Sepanlou SG, Emamian MH, Hadaegh F, Roohafza H, Hashemi H, Poustchi H, Pourshams A, Samavat T, Sharafkhah M, Talaei M, Van Klaveren D, Steyerberg EW, Khalili D\*. Prediction of Cardiovascular Disease Mortality in a Middle Eastern Country: Performance of the Globorisk and Score Functions in Four Population-Based Cohort Studies of Iran. *Int J Health Policy Manag*. 2022 Feb 1;11(2):210-217
294. Asgari S, Khalili D, Mehrabi Y, Hadaegh F\*. Letter to the Editor Regarding “Nationwide Prevalence of Diabetes and Prediabetes and Associated Risk Factors Among Iranian Adults: Analysis of Data from PERSIAN Cohort Study”. *Diabetes Therapy*. 2022 Jan;13(1):217-219.
295. Chavoshi V, Tamehri Zadeh SS, Khalili S, Rabbani A, Matini SAH, Mohsenifar Z, Hadaegh F\*. Long delay in diagnosis of a case with MEN1 due to concomitant presence of AIMAH with insulinoma: a case report and literature review. *BMC Endocr Disord*. 2022 Apr 21;22(1):108.
296. Chavoshi V, Barzin M, Ebadinejad A, Dehghan P, Momeni Moghaddam A, Mahdavi M, Hadaegh F, Niroomand M, Valizadeh M, Azizi F, Mirmiran P, Hosseinpanah F\*. Association of ideal cardiovascular health with carotid intima-media thickness (cIMT) in a young adult population. *Sci Rep*. 2022 Jun 16;12(1):10056
297. Hosseinpour-Niazi S, Hadaegh F, Mirmiran P\*, Daneshpour MS, Mahdavi M, Azizi F. Effect of legumes in energy reduced dietary approaches to stop hypertension (DASH) diet on blood pressure among overweight and obese type 2 diabetic patients: a randomized controlled trial. *Diabetol Metab Syndr*. 2022 May 13;14(1):72.
298. Ramezani Tehrani F\*, Behboudi-Gandevani S, Farzadfar F, Hosseinpanah F, Hadaegh F, Khalili D, Soleymani-Dodaran M, Valizadeh M, Abedini M, Rahmati M, Bidhendi Yarandi R, Torkestani F, Abdollahi Z, Bakhshandeh M, Zokaee M, Amiri M, Bidarpour F, Javanbakht M, Nabipour I, Nasli Esfahani E, Ostovar A, Azizi F. A Cluster Randomized Noninferiority Field Trial of Gestational Diabetes Mellitus Screening. *J Clin Endocrinol Metab*. 2022 Jun 16;107(7):e2906-e2920.
299. Asgari S, Masrouri S, Hosseinpour-Niazi S, Moslehi N, Azizi F, Hadaegh F\*. Association of ideal cardiovascular health metrics and incident type 2 diabetes mellitus among an urban population of Iran: One decade follow up in the Tehran Lipid and Glucose Study. *J Diabetes Investig*. 2022 May 19.

300. Sheklabadi E, Sharifi Y, Tabarraee M, Tamehrizadeh SS, Rabiee P, Hadaegh F\*. Adrenal hemorrhage following direct oral anticoagulant (DOAC) therapy: two case reports and literature review. *Thromb J*. 2022 Jul 5;20(1):39.
301. Asghari G, Mirmiran P\*, Rezaeemanesh A, Mahdavi M, Azizi F, Hadaegh F\*. Changes in ideal cardiovascular health among Iranian adolescents: 2007-2008 to 2015-2017. *BMC Pediatr*. 2022 Jul 26;22(1):450.
302. Ramezankhani A, Habibi-Moeini AS, Zadeh SST, Azizi F, Hadaegh F\*. Effect of family history of diabetes and obesity status on lifetime risk of type 2 diabetes in the Iranian population. *J Glob Health*. 2022 Aug 9;12:04068
303. Tamehri Zadeh SS, Khajavi A, Ramezankhani A, Azizi F, Hadaegh F\*. The impact of long-term exposure to PM10, SO2, O3, NO2, and CO on incident dysglycemia: a population-based cohort study. *Environ Sci Pollut Res Int*. 2022 Aug 9.
304. Tohidi M, Asgari S, Chary A, Azizi F, Hadaegh F\*. The association between low-density and non-high-density lipoprotein cholesterol with incident cardiovascular disease among low-risk Iranians during 2 decades follow-up. *Clin Biochem*. 2022 Aug 12:S0009-9120(22)00196-5
305. Hadaegh F\*, Hosseinpour-Niazi S, Deravi N, Hasheminia M, Moslehi N, Toreyhi H, Azizi F. Ideal cardiovascular health status and risk of cardiovascular disease and all-cause mortality: over a decade of follow-up in the Tehran lipid and glucose study. *Front Cardiovasc Med*. 2022 Aug 4;9:898681.
306. Deravi N, Moazzeni SS, Hasheminia M, Hizomi Arani R, Azizi F, Hadaegh F\*. Three-year weight change and risk of all-cause, cardiovascular, and cancer mortality among Iranian adults: over a decade of follow-up in the Tehran Lipid and Glucose Study. *BMC Public Health*. 2022 Sep 16;22(1):1762.
307. Hosseinpour-Niazi S, Mirmiran P\*, Hadaegh F, Daneshpour MS, Hedayati M, Azizi F. The effect of TCF7L2 polymorphisms on inflammatory markers after 16 weeks of legume-based dietary approach to stop hypertension (DASH) diet versus a standard DASH diet: a randomised controlled trial. *Nutr Metab (Lond)*. 2022 May 18;19(1):35
308. Hosseinpour-Niazi S, Mirmiran P\*, Hosseini S, Hadaegh F, Ainy E, Daneshpour MS, Azizi F. Effect of TCF7L2 on the relationship between lifestyle factors and glycemic parameters: a systematic review. *Nutr J*. 2022 Sep 26;21(1):59
309. Alizadeh Z, Baradaran HR\*, Kohansal K, Hadaegh F, Azizi F, Khalili D\*. Are the determinants of the progression to type 2 diabetes and regression to normoglycemia in the populations with pre-diabetes the same?. *Frontiers in Endocrinology*. 2022 Oct
310. Rasooli R, Ramezankhani A, Khalili D, Tohidi M, Hasheminia M, Azizi F, Hadaegh F\*. The relationship between glucose intolerance status and risk of hospitalization during two decades of follow-up: Tehran lipid and glucose study. *Ann Med*. 2022 Dec;54(1):3258-3268.
311. Masrouri S, Moazzeni SS, Cheraghloo N, Azizi F, Hadaegh F\*. The clinical value of metabolic syndrome and its components with respect to sudden cardiac death using different definitions: Two decades of follow-up from the Tehran Lipid and Glucose Study. *Cardiovasc Diabetol*. 2022 Dec 3;21(1):269.
312. Kohansal K, Masrouri S, Khalili D, Ramezankhani A, Azizi F, Blaha MJ, Hadaegh F\*. Changes in Fasting plasma glucose status and risk of mortality events in individuals without diabetes over two decades of Follow-up: a pooled cohort analysis. *Cardiovasc Diabetol*. 2022 Dec 3;21(1):267.
313. Asgari S, Masrouri S, Khalili D, Azizi F, Hadaegh F\*. Differences in the impact of impaired glucose status on clinical outcomes in younger and older adults: Over a decade of follow-up in the Tehran lipid and glucose study. *Front Cardiovasc Med*. 2022 Oct 31;9:1018403.
314. Moazzeni SS, Dehghani S, Hasheminia M, Hizomi Arani R, Azizi F, Hadaegh F\*. Three-year change in glycemic state and the future risk of incident hypertension among Iranian adults: Tehran Lipid and Glucose Study. *J Hum Hypertens*. 2022 Dec 6.

315. Tamehri Zadeh SS, Moazzeni SS, Asgari S, Mirbolouk M, Azizi F, Hadaegh F\*. Association between Wrist Circumference and Risk of Any Fracture in Adults: Findings from 15 Years of Follow-Up in the Tehran Lipid and Glucose Study. *J Clin Med*. 2022 Nov 29;11(23):7048.
316. Matsushita K, Kaptoge S, Hageman SH, Sang Y, Ballew SH, Grams ME, Surapaneni A, Sun L, Arnlov J, Bozic M, Brenner H, Brunskill NJ, Chang AR, Chinnadurai R, Cirillo M, Correa A, Ebert N, Eckardt KU, Gansevoort RT, Gutierrez O, Hadaegh F, He J, Hwang SJ, Jafar TH, Jassal SK, Kayama T, Kovesdy CP, Landman GW, Levey AS, Lloyd-Jones DM, Major RW, Miura K, Muntner P, Nadkarni GN, Nowak C, Ohkubo T, Pena MJ, Polkinghorne KR, Sairenchi T, Schaeffner E, Schneider MP, Shalev V, Shlipak MG, Solbu MD, Stempniewicz N, Tollitt J, Valdivielso JM, van der Leeuw J, Wang AYM, Wen CP, Woodward M, Yamagishi K, Yatsuya H, Zhang L, Dorresteijn JA, Di Angelantonio E, Visseren FL, Pennells L, Coresh J; Chronic Kidney Disease Prognosis Consortium. Including Measures of Chronic Kidney Disease to Improve Cardiovascular Risk Prediction by SCORE2 and SCORE2-OP. *Eur J Prev Cardiol*. 2023 Jan 11;30(1):8-16.
317. Kohansal K, Ahmadi N, Hadaegh F, Alizadeh Z, Azizi F, Habibi-Moeini AS\*, Khalili D\*. Determinants of the progression to type 2 diabetes and regression to normoglycemia in people with pre-diabetes: A population-based cohort study over ten years. *Prim Care Diabetes*. 2022 Dec;16(6):797-803.
318. Ramezankhani A, Azizi F, Hadaegh F\*. Gender differences in changes in metabolic syndrome status and its components and risk of cardiovascular disease: a longitudinal cohort study. *Cardiovasc Diabetol*. 2022 Nov 2;21(1):227.
319. Masrouri S, Cheraghi L, Deravi N, Cheraghloo N, Tohidi M, Azizi F, Hadaegh F\*. Mean versus variability of lipid measurements over 6 years and incident cardiovascular events: More than a decade follow-up. *Front Cardiovasc Med*. 2022 Dec 9;9:1065528
320. Afaghi S, Ramezankhani A, Azizi F, Hadaegh F\*. Gender-specific effect of outdoor temperature and seasonal variation on blood pressure components: a cross-sectional study on Iranian adults from 2015 to 2018. *Environ Sci Pollut Res Int*. 2023 Feb 8.
321. Amiri M, Ahmadi N, Hadaegh F, Mousavi M, Azizi F, Ramezani Tehrani F\*. Does the addition of serum antimüllerian hormone concentrations to the Framingham Risk Score and Pooled Cohort Equations improve the prediction of cardiovascular disease? *Menopause*. 2023 Jan 31.
322. Asghari G, Nikparast A, Mahdavi M, Dehghan P, Valizadeh M, Hosseinpanah F, Azizi F, Hadaegh F\*. Diagnostic performance of different anthropometric indices among Iranian adolescents for intima media thickness in early adulthood: A prospective study and literature review. *Front Nutr*. 2023 Feb 28;10:1098010.
323. Ramezankhani A, Azizi F, Hadaegh F\*. Lifetime risk of cardiovascular disease stratified by traditional risk factors: findings from the cohort of Tehran Lipid and Glucose Study. *Hellenic J Cardiol*. 2023 Mar 11;S1109-9666(23)00034-9.
324. Habibi D, Daneshpour MS, Asgarian S, Kohansal K, Hadaegh F, Mansourian M,\* Akbarzadeh M\*. Effect of C-reactive protein on the risk of Heart failure: a mendelian randomization study. *BMC Cardiovasc Disord*. 2023 Mar 7;23(1):112.
325. Ramezani Tehrani F, Rahmati M, Farzadfar F, Abedini M, Farahmand M, Hosseinpanah F, Hadaegh F, Torkestani F, Valizadeh M, Azizi F, Behboudi-Gandevani S\*. One-step versus two-step screening for diagnosis of gestational diabetes mellitus in Iranian population: A randomized community trial. *Front Endocrinol (Lausanne)*. 2023 Feb 2;13:1039643.
326. Tamehri Zadeh SS, Khajavi A, Ramezankhani A, Azizi F, Hadaegh F\*. The impact of long-term exposure to PM10, SO2, O3, NO2, and CO on incident dysglycemia: a population-based cohort study. *Environ Sci Pollut Res Int*. 2023 Jan;30(2):3213-3221.
327. Tohidi M, Asgari S, Chary A, Safiee S, Azizi F, Hadaegh F\*. Association of triglycerides to high-density lipoprotein cholesterol ratio to identify future prediabetes and type 2 diabetes mellitus: over one-decade follow-up in the Iranian population. *Diabetol Metab Syndr*. 2023 Feb 2;15(1):13.

328. Khalili D\*, Khayamzadeh M, Kohansal K, Ahanchi NS, Hasheminia M, Hadaegh F, Tohidi M, Azizi F, Habibi-Moeini AS. Are HOMA-IR and HOMA-B good predictors for diabetes and pre-diabetes subtypes? *BMC Endocr Disord*. 2023 Feb 14;23(1):39.
329. Fahimfar N, Kohansal K, Asgari S, Ostovar A, Hadaegh F, Khalili D\*. The Trend of Risk for Cardiovascular Diseases During the Past Decade in Iran, Applying No-Lab and Lab-Based Prediction Models. *Glob Heart*. 2023 Feb 10;18(1):3
330. NCD Risk Factor Collaboration (NCD-RisC). Diminishing benefits of urban living for children and adolescents' growth and development. *Nature*. 2023 Mar;615(7954):874-883.
331. Masrouri S, Alijanzadeh D, Amiri M, Azizi F, Hadaegh F\*. Predictors of decline in kidney function in the general population: a decade of follow-up from the Tehran Lipid and Glucose Study. *Ann Med*. 2023 Dec;55(1):2216020.
332. Deravi N, Sharifi Y, Koochi F, Zadeh SST, Masrouri S, Azizi F, Hadaegh F\*. The association between fasting plasma glucose variability and incident eGFR decline: evidence from two cohort studies. *BMC Public Health*. 2023 Mar 27;23(1):565.
333. Ramezankhani A, Azizi F, Hasheminia M, Hadaegh F\*. The impact of general and central obesity for all-cause hospitalization among Iranian adults: a 20 year follow-up-results from the TLGS cohort. *BMC Public Health*. 2023 May 18;23(1):903.
334. Hadaegh F, Abdi A, Kohansal K, Hadaegh P, Azizi F, Tohidi M\*. Gender differences in the impact of 3-year status changes of metabolic syndrome and its components on incident type 2 diabetes mellitus: a decade of follow-up in the Tehran Lipid and Glucose Study. *Front Endocrinol (Lausanne)*. 2023 May 25;14:1164771.
335. Daneshpour MS\*, Akbarzadeh M, Lanjanian H, Sedaghati-Khayat B, Guity K, Masjoudi S, Zahedi AS, Moazzam-Jazi M, Bonab LNH, Shalbafan B, Asgarian S, Farhood GK, Javanrooh N, Zarkesh M, Riahi P, Moghaddas MR, Dehkordi PA, Ahmadi AD, Hosseini F, Farahani SJ, Hadaegh F, Mirmiran P, Tehrani FR, Ghanbarian A, Pasand MSFM, Amiri P, Valizadeh M, Hosseipanah F, Tohidi M, Ghasemi A, Zadeh-Vakili A, Piryaeei M, Alamdari S, Khalili D, Momenan A, Barzin M, Zeinali S, Hedayati M, Azizi F\*. Cohort profile update: Tehran cardiometabolic genetic study. *Eur J Epidemiol*. 2023 Jun;38(6):699-711.
336. Kabootari M, Tamehri Zadeh SS, Hasheminia M, Azizi F, Hadaegh F\*. Change in blood pressure status defined by 2017 ACC/AHA hypertension guideline and risk of cardiovascular disease: Results of over a decade of follow-up of the Iranian population. *Frontiers in Cardiovascular Medicine*.;10:998.
337. Asgari S, Khalili D, Azizi F, Hadaegh F\*. External validation of the American prediction model for incident type 2 diabetes in the Iranian population. *BMC Med Res Methodol*. 2023 Mar 29;23(1):77.
338. Asgari S\*, Molavizadeh D, Tohidi M, Momenan AA, Azizi F, Hadaegh F\*. Prevalence and metabolic determinants of abnormal alanine aminotransferase: A cross-sectional study of Iranian adults, 2018-2022. *J Clin Lab Anal*. 2023 Jul 5:e24937.
339. Afaghi S, Esmaeili F, Azizi F, Hadaegh F\*. Gender differences in change of metabolic syndrome status and its components on all-cause and cause-specific mortalities: Over a decade follow-up study. *Nutr Metab Cardiovasc Dis*. 2023 Jul 20:S0939-4753(23)00292-2.
340. Masrouri S1, Tamehri Zadeh SS1, Pishgahi M, Azizi F, Shapiro MD, Hadaegh F\*. Kidney function decline is associated with mortality events: over a decade of follow-up from Tehran Lipid and Glucose Study. *J Nephrol*. 2023 Sep 4.
341. Rahmani F, Tohidi M\*, Azmoudeh-Ardalan F, Sadeghi A, Hadaegh F. Diagnostic dilemma in a patient with history of medullary thyroid carcinoma and abnormal serum liver enzymes; a case report with six years follow up. *BMC Endocr Disord*. 2023 Aug 30;23(1):186
342. Hosseinpour-Niazi S, Bakhshi B, Mirmiran P\*, Gaeni Z, Hadaegh F, Azizi F. Effect of weight change on the association between overall and source of carbohydrate intake and risk of metabolic syndrome: Tehran lipid and glucose study. *Nutr Metab (Lond)*. 2023 Sep 12;20(1):39.



343. Ramezankhani A, Azizi F, Hadaegh F\*. Association between estimated glomerular filtration rate slope and cardiovascular disease among individuals with and without diabetes: a prospective cohort study. *Cardiovasc Diabetol*. 2023 Oct 4;22(1):270.
344. Ramezani Tehrani F, Farzadfar F, Hosseinpanah F, Rahmati M, Firouzi F, Abedini M, Hadaegh F, Valizadeh M, Torkestani F, Khalili D, Solaymani-Dodaran M, Bidhendi-Yarandi R, Bakhshandeh M, Ostovar A, Dovom MR, Amiri M, Azizi F, Behboudi-Gandevani S\*. Does fasting plasma glucose values 5.1-5.6 mmol/l in the first trimester of gestation a matter? *Front Endocrinol (Lausanne)*. 2023 Jun 2;14:1155007.
345. NCD Risk Factor Collaboration. Hadaegh F. Estimated Glomerular Filtration Rate, Albuminuria, and Adverse Outcomes: An Individual-Participant Data Meta-Analysis. *JAMA*. 2023 Oct 3;330(13):1266-1277.
346. Zadeh SS, Khajavi A, Tohidi M, Azizi F, Hadaegh F\*. Impact of short-and long-term exposure to air pollution on lipid profile in adults aged 20 to 69 years in Tehran Province, Iran. *Atmospheric Environment*. 2023 Aug
347. Hosseinpour-Niazi S, Afaghi S, Hadaegh P, Mahdavi M, Farhadnejad H, Tohidi M, Mirmiran P, Azizi F, Hadaegh F\*. The association between metabolic syndrome and insulin resistance with risk of cardiovascular events in different states of cardiovascular health status. *J Diabetes Investig*. 2023 Oct 24.
348. Moazzeni SS, Karimi Toudeshki K, Ghorbanpouryami F, Hasheminia M, Azizi F, Pishgahi M, Hadaegh F\*. Resting heart rate and the risk of incident type 2 diabetes mellitus among non-diabetic and prediabetic Iranian adults: Tehran lipid and glucose study. *BMC Public Health*. 2023 Oct 27;23(1):2112.
349. Ramezankhani A, Mehrabi Y, Azizi F, Hosseinpanah F, Dehghan P, Hadaegh F\*. Cumulative burden and trajectories of body mass index and blood pressure from childhood and carotid intima-media thickness in young adulthood. *Prev Med*. 2023 Oct 26:107747.
350. Masrouri S, Afaghi S, Khalili D, Shapiro MD, Hadaegh F\*. Cumulative Blood Pressure in Early Adulthood and Coronary Artery Calcium and Carotid Intima-Media Thickness in Middle Age Among Adults With Maintained Blood Pressure of <130/80 mm Hg: A Post Hoc Analysis. *J Am Heart Assoc*. 2023 Dec 8:e032091.
351. Ramezankhani A, Azizi F, Hadaegh F\*. Sex differences in risk factors for coronary heart disease events: a prospective cohort study in Iran. *Sci Rep*. 2023 Dec 16;13(1):22398.
352. Rahmani F, Asgari S, Azizi F, Hadaegh F\*. The association of ideal cardiovascular health metrics and incident hypertension among an urban population of Iran: a decade follow-up in Tehran Lipid and Glucose Study. *J Hum Hypertens*. 2023 Dec 18.
353. Kohansal K, Afaghi S, Khalili D, Molavizadeh D, Hadaegh F\*. Gender differences in midlife to later-life cumulative burden and variability of obesity measures and risk of all-cause and cause-specific mortality. *Int J Obes (Lond)*. 2023 Dec 19.
354. Golmohamadi M, Hosseinpour-Niazi S, Hadaegh P, Mirmiran P\*, Azizi F, Hadaegh F\*. Association between Dietary Antioxidants intake and the Risk of Type 2 Diabetes Mellitus in a Prospective Cohort Study: Tehran Lipid and Glucose Study. *Br J Nutr*. 2023 Dec 20:1-24.
355. Ramezani Tehrani F, Sheidaei A, Rahmati M, Farzadfar F, Noroozadeh M, Hosseinpanah F, Abedini M, Hadaegh F, Valizadeh M, Torkestani F, Khalili D, Firouzi F, Solaymani-Dodaran M, Ostovar A, Azizi F, Behboudi-Gandevani S. Various screening and diagnosis approaches for gestational diabetes mellitus and adverse pregnancy outcomes: a secondary analysis of a randomized non-inferiority field trial. *BMJ Open Diabetes Res Care*. 2023 Dec 12;11(6):e003510.
356. Masrouri S, Esmaeili F, Tohidi M\*, Azizi F, Hadaegh F\*. Rapid decline of kidney function increases fracture risk in the general population: Insights from TLGS. *Bone*. 2024 Feb;179:116974.
357. Alizadeh F, Tohidi M\*, Hasheminia M, Hosseini-Esfahani F, Azizi F, Hadaegh F. Association of ideal cardiovascular health metrics with incident low estimated glomerular filtration rate: More than a decade follow-up in the Tehran Lipid and Glucose Study (TLGS). *PLoS One*. 2024 Feb 1;19(2):e0282773.

358. Masrouri S, Shapiro MD, Khalili D, Hadaegh F\*. Impact of Coronary Artery Calcium on Mortality and Cardiovascular Events in Metabolic Syndrome and Diabetes among Younger Adults. *Eur J Prev Cardiol.* 2024 Feb 7:zwae039.

359. Abdi A, Kohansal K, Khalili D, Azizi F, Hadaeagh F\*. The difference between 2-hour post-challenge and fasting plasma glucose associates with the risk of cardiovascular disease in a normoglycemic population: the Tehran lipid and glucose study. *Nutr Metab (Lond)*. 2024 Feb 22;21(1):10.
360. Asgari S, Molavizadeh D, Soltani K, Khalili D, Azizi F, Hadaeagh F\*. The impact of obesity on different glucose tolerance status with incident cardiovascular disease and mortality events over 15 years of follow-up: a pooled cohort analysis. *Diabetol Metab Syndr*. 2024 Jan 25;16(1):27.
361. Khalili S, Zakeri A, Hadaeagh F, Zadeh SST. Neglected Adrenal Hypoplasia Congenita in Two Siblings with Novel Genetic Mutations in NR0B1 Gene and Notable Clinical Course: A Case Report. *Endocr Metab Immune Disord Drug Targets*. 2024 Feb 21.
362. NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in underweight and obesity from 1990 to 2022: a pooled analysis of 3663 population-representative studies with 222 million children, adolescents, and adults. *Lancet*. 2024 Feb 29:S0140-6736(23)02750-2.
363. Ramezankhani A, Azizi F, Hadaeagh F\*. Tracking correlations and predictors of plasma glucose in young adulthood: A comprehensive analysis from adolescence to young adulthood in TLGS study. *Diabetes Res Clin Pract*. 2024 Mar 20;210:111632.
364. Masrouri S, Tamehri Zadeh SS, Shapiro MD, Khalili D, Hadaeagh F\*. Impact of optimal cholesterol levels on subclinical atherosclerosis in the absence of risk factors in young adults. *Atherosclerosis*. 2024 Mar 17:117520.